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s always, the 56th Annual Scientific Session of the
merican College of Cardiology (ACC) set out to present
he latest innovations, medical updates, and new technolo-
ies in cardiovascular medicine, but the 2007 meeting also
ought to present this information in more innovative ways
hat would be more useful to cardiologists. Consequently,
he annual meeting included more video case studies, live
resentations from leading medical centers around the
orld, and e-posters that allowed imbedded multimedia
mages. The e-posters remain available for viewing at
ardiosource, along with other online coverage of the
nnual meeting.
As part of the effort to make new information applicable
o the day-to-day problems of cardiologists, there was a
hange in the format of the closing symposium that reviews
he meeting’s most important and interesting presentations.
his supplement to the Journal of the American College of
ardiology ( JACC) presents the Highlights of the Annual
cientific Session, which for the first time were presented as
Conversation With the Experts. Rather than a comprehen-
ive examination of all major presentations, short summaries
f individual presentations were reviewed in an effort to
rovide the most important insights and bullet points of the
eeting, followed by a spirited discussion from a panel of
xperts.
The Highlights Session was chaired by E. Murat Tuzcu,
D, FACC, Chair of the 2007 Annual Scientific Session
rogram Committee. He was joined on the panel by his
ommittee co-chairs, Randall C. Starling, MD, MPH,
ACC, and James D. Thomas, MD, FACC. Summaries of
riginal research and structured sessions were prepared and
resented by the coordinators of the topic working groups
rom the Program Planning Committee.
James H. Stein, MD, FACC, led off the ACC.07 and i2
ummit Highlights covering Vascular Disease, Hyperten-
ion, and Prevention. This topic attracted 22.2% of the
bstract submissions for ACC.07, which was the highest
ercentage of overall submissions for any topic in more than
decade. Robert A. Harrington, MD, FACC, was the topic
oordinator who summarized key themes and important
essages to emerge from the sessions on Myocardial Isch- lmia and Infarction. William D. Knopf, MD, FACC,
repared the highlights of the Innovation in Intervention: i2
ummit, along with his co-chairs, David Holmes, Jr., MD,
ACC, FSCAI, and Barry Uretsky, MD, FACC, FSCAI.
alvular Heart Disease was addressed by Samir R. Kapadia,
D, FACC, and highlights relating to Cardiac Function
nd Heart Failure were summarized by Lynne E. Wagoner,
D, FACC. Steven Markowitz, MD, FACC, reviewed
ardiac Arrhythmias and Flordeliza Villanueva, MD,
ACC, presented the highlights related to Imaging and
iagnostic Testing. According to Dr. Tuzcu, John Rhodes,
r., MD, FACC, probably created the largest, most diverse
ongenital heart disease track of any previous ACC sessions,
nd he presented highlights in Pediatric Cardiology and
dult Congenital Heart Disease. JoAnne Foody, MD,
ACC, had 1 of the toughest tasks because Special Topics
ncompasses a broad range of investigations that may be
ard to classify but are of great importance. Special Topics
nclude subjects as diverse as assessing and improving
ardiovascular health care quality and the measurement of
he impact of cardiovascular informatics. Finally, the dis-
ussants included 2 of the College’s leading editors: An-
hony N. DeMaria, MD, FACC, Editor-in-Chief of JACC,
nd C. Richard Conti, MD, MACC, Editor-in-Chief of
CCEL.
This supplement to JACC presents the highlights of this
onversation With the Experts and features more detailed
ummaries of the individual presentations covered during
he final session; plus, there is additional artwork and
eferences that can be used to find the many sessions with
ull audio and video that are available online at ACC’s
ardiosource. After the session highlights are summarized,
he panelists provide important perspectives on the topics
iscussed and help discern what the data mean for clinical
ractice.
ascular Disease, Hypertension, and Prevention
here were 424 presentations related to vascular disease,
ypertension, and prevention at the ACC.07 Scientific
ession, including disappointing results from trials targeting
igh-density lipoprotein (HDL) cholesterol. However, the
ews was decidedly better for drugs that lower low-density
ipoprotein (LDL) cholesterol and for studies evaluating
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August 21, 2007:C2–31 ACC 2007 Annual Session Highlightscreening tests used to assess cardiac risk. These presenta-
ions were selected from a total of 1,181 abstracts on these
pecific topics that were submitted to the Program Planning
ommittee.
High-density lipoprotein cholesterol is an attractive tar-
et for reducing cardiovascular risk because of epidemiologic
vidence demonstrating a strong inverse relationship be-
ween HDL cholesterol levels and cardiovascular risk. The
ationale for increasing HDL cholesterol levels as a thera-
eutic strategy is further supported by evidence of the
ipoprotein’s anti-inflammatory properties, antioxidant ef-
ects, and ability to promote reverse cholesterol transport.
Abbreviations and Acronyms
ACHD  adult congenital heart disease
ACS  acute coronary syndrome
ADHF  acute decompensated heart failure
AF  atrial fibrillation
AMI  acute myocardial infarction
AS  aortic stenosis
BMS  bare-metal stent(s)
CAD  coronary artery disease
CHD  coronary heart disease
CI  confidence interval
CIMT  carotid intima-media thickness
CMR  cardiac magnetic resonance
CRT  cardiac resynchronization therapy
CT  computed tomography
CTA  computed tomography angiography
DES  drug-eluting stent(s)
FDG  fluorodeoxyglucose
HDL  high-density lipoprotein
ICD  implantable cardioverter-defibrillator
LDL  low-density lipoprotein
LV  left ventricular
LVAD  left ventricular assist device
LVEF  left ventricular ejection fraction
MACE  major adverse cardiac events
MI  myocardial infarction
MPI  myocardial perfusion imaging
MR  mitral regurgitation
MV  mitral valve
MVR  mitral valve replacement
NNT  number needed to treat
NYHA  New York Heart Association
ox-LDL  oxidized low-density lipoprotein
PCI  percutaneous coronary intervention
PET  positron emission tomography
PHV  percutaneous heart valve
PPAR  peroxisome proliferator-activated receptors
PPM  patient prosthesis mismatch
PVAD  percutaneously placed continuous-flow left ventricular assist device
SES  sirolimus-eluting stent(s)
STEMI  ST-segment elevation myocardial infarction
TIMI  Thrombolysis In Myocardial Infarction
TRA  thrombin receptor antagonist
TWA  T-wave alternansr. Stein began by noting the abundance of bad news felating to drugs in development for raising HDL cho-
esterol levels. Torcetrapib, a cholesterol-ester transfer
rotein inhibitor, was tested versus atorvastatin in the
LLUSTRATE (Investigation of Lipid Level Manage-
ent to Understand Its Impact in Atherosclerotic Events)
rial (1) and the RADIANCE 1 and RADIANCE 2
Rating Atherosclerotic Disease Change by Imaging with a
ew Cholesteryl Ester Transfer Protein [CETP] Inhibitor)
rials (2–4). In these studies, there were large increases in
DL cholesterol levels (60%) and a substantial decrease
n levels of LDL cholesterol (20%) (Table 1), yet there
as no significant decrease in the progression of coronary
therosclerosis. Indeed, one secondary end point of RADI-
NCE 1 suggested progression of disease in torcetrapib-
reated patients based on measurement of carotid intima-
edia thickness (CIMT) studies.
One issue still to be resolved is whether the failure of
orcetrapib is due to the molecule or the mechanism (5).
hether that question gets answered or not, the data
afety and monitoring board for the ILLUSTRATE trial
ecommended that the study be terminated. Pfizer sub-
equently halted its torcetrapib research program. (In the
nterest of patient safety, Pfizer stopped all torcetrapib
linical trials.) (6).
In theERASE (Effects of ReconstitutedHDLonAthero-
clerosis) trial, treatment with CSL-111, which chemically
nd biologically resembles native HDL, was not superior to
lacebo in the primary efficacy end point of percent change
n coronary atheroma volume (7). However, CSL-111 did
ead to significant differences in 3 secondary efficacy end
oints: change in atheroma volume versus baseline, change
n plaque characterization indexes, and change in coronary
core on quantitative coronary angiography.
Another approach under study uses peroxisome proliferator-
ctivated receptors (PPARs). Although the results of early
rials were disappointing, a series of PPAR agonists have
een described, leading to the discovery of LY518674, a
ighly potent and selective PPAR agonist. However, in data
resented at ACC.07, LY518674 proved to be no better
han fenofibrate (Table 2); plus, it increased the level of
erum creatinine compared with placebo (p  0.001), with
any patients experiencing serum creatinine values exceed-
ng the upper limits of normal (8). Also, the PPAR agonist
as associated with what Dr. Stein called “a very odd dose
esponse.” Specifically, there were unusual dose-response
urves; for example, the greatest elevation of HDL was
ound with the intermediate LY518674 dose (25 g),
hereas the 100-g dose produced almost no effect on these
ipids. Furthermore, the study drug had a significantly
nfavorable effect on LDL compared with fenofibrate,
ncreasing LDL by 18.3% (50 g) and 19.5% (100 g),
ersus 2.3% with fenofibrate (p  0.002 for both compar-
sons). The results of this study were published simulta-
eously in JAMA (9). “Overall there was not very good news
or raising HDL cholesterol at this meeting,” said Dr. Stein,
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ACC 2007 Annual Session Highlights August 21, 2007:C2–31but we have to remember that we have an excellent HDL
holesterol-raising drug already available, which is niacin.”
he METEOR Trial
he news was decidedly better for drugs that lower LDL
nd the screening tests used to assess risk. The METEOR
Measuring Effects on Intima-Media Thickness: an Evalu-
tion of Rosuvastatin) study investigated the effect of a
0-mg dose of rosuvastatin on CIMT during the course of
years in middle-aged individuals with low Framingham
isk scores (10% risk over 10 years) but with evidence of
ubclinical atherosclerosis (10). The results, published si-
ultaneously (11), indicated that rosuvastatin was associ-
ted with a 49% reduction in LDL cholesterol, a 34%
eduction in total cholesterol, an 8% increase in HDL, and
16% reduction in triglycerides. Compared with placebo,
tatin therapy significantly slowed progression of maximum
IMT for 12 carotid sites (Table 3). Moreover, although
here was significant progression of atherosclerosis in the
lacebo group, no significant disease progression was ob-
erved in the rosuvastatin group. According to Dr. Stein,
This is the first step in showing us that people with
dvanced subclinical atherosclerosis may benefit from ag-
ressive lipid-lowering therapy.”
Data also were presented analyzing a new drug, ISIS-
0102, which is an oligonucleotide that inhibits apolipopro-
ein B (apoB) and as a result lowers LDL cholesterol and
riglycerides by 50% on top of statin therapy (12,13). Taken
ffect of Atorvastatin and Torcetrapib on LDL and HDL Cholesterol
Table 1 Effect of Atorvastatin and Torcetrapib on LDL and HDL
ILLUSTRATE
Atorvastatin
Only
(A)
Atorvastatin/
Torcetrapib
(T/A)
LDL at 24 months (mg/dl) 87.2 70.1
Change from baseline 3.4% 15.6%
p value 0.001*
HDL at 24 months (mg/dl) 43.9 72.1
Change from baseline 2.9% 56.7%
p value 0.001*
T/A versus A at 24 months. †T/A versus A change at 24 months from baseline.
FH  familial hyperlipidemia; HDL  high-density lipoprotein; LDL  low-density lipoprotein.
Atherogenic Dyslipidemia Study: Change in LipoFrom Baseline Until Follow-Up Visit
Table 2 Atherogenic Dyslipidemia Study: ChFrom Baseline Until Follow-Up Visit
Placebo Fenofibrate
Total cholesterol 1.4% 6.0%
LDL 0.3% 2.3%
HDL 1.1% 14.4%
Triglycerides 1.4% 32.8%
Non–HDL 0.7% 10.6%
apoB 0.1% 8.1%
apoAI 2.3% 8.7%
apoAII 0.3% 17.0%apo  apolipoprotien; HDL  high-density lipoprotein; LDL  low-density lipoogether with the METEOR trial results, Dr. Stein said,
This is very exciting because it shows we’ve been on the
ight track. It extends the population of patients in whom
ggressive lipid-lowering therapy can be beneficial and it
ives us some insight into what the future is going to look
ike: very specific compounds that go right to the liver to
lock apoB production.”
The METEOR trial was not the only one presented at
CC.07 suggesting value to using imaging as screening
ests. The measurement of CIMT has been used mostly as
research tool and only as a clinical tool at selected centers
ecause it is difficult to perform. However, data by Gepner
t al. (14) showed that an abbreviated CIMT screening
rotocol, focusing on plaque at the common carotid artery,
as just as good as a more complicated research protocol
area under the curve 0.848, p  0.001).
More good news for screening tests emerged from an
nalysis of asymptomatic participants of the MESA (Multi-
thnic Study of Atherosclerosis) study (15). There is a
onsensus that coronary calcified plaque measured by car-
iac computed tomography (CT) predicts incident coronary
eart disease (CHD) and that the prevalence of calcified
laque varies by race in the U.S. However, few studies have
een undertaken related to the prediction of cardiac-related
vents in American minority groups. The MESA investi-
ators evaluated the impact of coronary artery calcium score
s it relates to future cardiac events in 4 major U.S. ethnic
roups: Caucasians, Asian Americans, African Americans,
USTRATE, RADIANCE 1, and RADIANCE 2
esterol in ILLUSTRATE, RADIANCE 1, and RADIANCE 2
RADIANCE 1
(Heterozygous FH)
RADIANCE 2
(Mixed Hyperlipidemia)
rvastatin
Only
(A)
Atorvastatin/
Torcetrapib
(T/A)
Atorvastatin
Only
(A)
Atorvastatin/
Torcetrapib
(T/A)
43.2 115.1 83.8 102.7
6.3% 14.4% 4.4% 13.3%
0.001† 0.001†
52.4 81.5 46.6 77.3
2.5% 54.4% 1.8% 61.6%
0.001† 0.001†
in Levels
in Lipoprotein Levels
g LY 25 g LY 50 g LY 100 g
3% 4.4% 0.8% 2.4%
1% 11.9% 18.3% 19.5%
6% 15.8% 11.1% 2.1%
1% 40.9% 41.7% 34.9%
8% 9.1% 1.9% 3.5%
9% 6.5% 1.4% 2.5%
0% 10.3% 7.6% 4.2%
8% 21.6% 27.6% 30.0%in ILL
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August 21, 2007:C2–31 ACC 2007 Annual Session Highlightsnd Hispanics. A total of 6,726 individuals without CHD at
tudy entry underwent coronary risk factor evaluation,
ardiac CT scanning for coronary artery calcium measure-
ent, and clinical follow-up for 35.4 months. Cox regres-
ion of coronary artery calcium and Framingham risk score
s predictors of CHD events in the 4 ethnic groups resulted
n hazard ratios for calcium (per unit change in log trans-
ormed calcium score) of 1.4 for Caucasians, 1.8 for Chi-
ese, 1.7 for African Americans, and 1.4 for Hispanics (all
 0.001). Dr. Stein said, “That was a major gap in the
iterature. We didn’t have data on a large, relatively unse-
ected group of people. This really helps fill that gap.”
Finally, just how large is the low-risk population evalu-
ted in the METEOR trial? Dr. Stein said that a sense of
he size of this population can be seen in results of the
allas Heart Study presented at ACC.07 (16). Fully 27% to
3% of participants in the Dallas Heart Study with calcium
cores 400 had low Framingham risk scores.
uestion and Answer
r. Thomas: I chaired the late-breaking clinical trial session
eaturing the ILLUSTRATE and RADIANCE trials. It
as really striking how negative they were. There was a
oncern about increased blood pressure with torcetrapib as
he possible fly in the ointment that prevented this approach
rom being more useful. I was very interested in the
omments by Daniel J. Rader, MD, one of our panelists and
he presenter of this year’s Louis F. Bishop lecture, which
as a wonderful basic summary of where we are with HDL
aising and where we may be able to go from there. He
howed some data from preclinical studies of another
holesteryl ester transfer protein inhibitor that appears to
ave no associated blood pressure problem. So, the ILLUS-
RATE and RADIANCE data may not be a class effect
ut rather a molecule effect with this particular drug.
r. DeMaria: One of the most intriguing aspects of these
resentations was the implication regarding surrogate end
ffect of Rosuvastatin on Progression of Carotidrt ry IMT in Low-Risk I dividual n theETEOR r al
Table 3
Effect of Rosuvastatin on Progression of Carotid
Artery IMT in Low-Risk Individuals in the
METEOR Trial
Rosuvastatin
(n  624)
Placebo
(n  254) p Value
IMT slope (mm/yr)
Max IMT all sites* 0.0014 0.0131 0.0001
Max IMT CCA sites 0.0038 0.0084 0.0001
Max IMT ICA sites 0.0039 0.0145 0.023
Max IMT bulb sites 0.0040 0.0172 0.0001
% change LDL† 48.8 0.3 0.0001
% change HDL† 8.0 2.8 0.0001
% change LDL/HDL† 51.2 0.7 0.0001
% change apoB/apoA1 41.5 4.5 0.0001
values shown for between groups: *primary end point; †time-weighted average.
apo  apolipoprotien; CCA  common carotid artery; HDL  high-density lipoprotein; ICA 
nternal carotid artery; IMT  intima-media thickness; LDL  low-density lipoprotein; Max 
aximum.oints. As you know, there has been a major debate: can we iook at CIMT or intravascular ultrasound and predict how
drug will behave? Given the progression of disease that
as reported, it suggests that the surrogates may still
rovide a basic first step, a relatively inexpensive way to
creen drugs.
r. Stein: That’s definitely my take on it. In fact, it has been
aid that by conducting morbidity and mortality trials in
onjunction with imaging trials, the imaging trials serve as a
ata and safety monitoring referendum about the safety of
hese trials and these medications. If you have a medication
hat does not slow atherosclerosis, it really closes the door
n proving that the drug will eventually reduce cardiac
vents.
r. Starling: Jim, help me interpret the data. Where are we
eaded with statin therapy in the context of “apparently
ow-risk patients”?
r. Stein: I certainly don’t think we can take a total
opulation approach and just say, “Everyone needs to be on
statin.” But we do need to be smarter about identifying
ho among those low-risk patients needs to be treated.
fter all, most heart attacks occur in people who are at low
isk. It’s just that this is such a large group of people and
aybe noninvasive imaging or, perhaps, some new biomar-
ers can help us be smarter about who we treat rather than
ust treating more people.
r. Tuzcu: Jim, the authors of the Dallas Heart Study
ound that in the intermediate-risk group, calcium screening
id not add much. The data suggested that you would have
o scan 100 women and about 60 men to get 1 benefit as far
s risk assessment. We have previously thought that screen-
ng was going to be important in the intermediate-risk
roup. So what’s going on?
r. Stein: The intermediate-risk group of patients in the
.S. is quite small; it’s between 5% and 15% of the U.S.
opulation. The majority of people who have advanced
ubclinical atherosclerosis are in the low-risk group; there-
ore, we need to be smarter about finding those people and
hat’s what explains that difference.
r. Conti: Jim, I’m all for doing CT. Principally, I like CT
ngiography, but CT calcium screening is here to stay.
hat do you do with that information if you don’t have the
raditional risk factors? How do you handle an elevated
oronary calcium score in these patients?
r. Stein: That’s a critical point. None of these tests have
ny value in isolation. In fact, you really shouldn’t make your
ay to any one of these tests unless you’ve looked at risk
actors. And by no means should people take these studies
o mean that risk factors don’t predict anything and they’re
ot useful. They are useful; they get us on a starting page
nd tell us what should be the target of treatment if
omething is wrong.
yocardial Ischemia and Infarction
here were 274 abstracts related to myocardial ischemia and
nfarction that were accepted for presentation at the
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ACC 2007 Annual Session Highlights August 21, 2007:C2–31CC.07 Scientific Session, including the 1-year results of
he ACUITY (Acute Catheterization and Urgent Interven-
ion Triage Strategy) trial, which evaluated bivalirudin for
cute coronary syndrome (ACS); MERLIN-TIMI 36
Metabolic Efficiency with Ranolazine for Less Ischemia
n Non-ST Elevation Acute Coronary Syndromes–
hrombolysis In Myocardial Infarction 36), providing
ong-term safety data on ranolazine in a high-risk pop-
lation of patients; and the effects of a novel antioxidant/
nti-inflammatory agent to reduce ACS-related events.
lus, a number of papers evaluated new approaches to
educe complications or better discriminate high-risk pa-
ients. These presentations were selected from a total of 796
bstracts on these topics that were submitted to the Pro-
ram Committee.
In summarizing key themes and identifying important
reas of research in myocardial ischemia and infarction,
r. Harrington began with the category of non–ST-
egment elevation ACS. He noted there was a wealth of
linical trial data presented at ACC.07 and the i2 Summit.
One-year follow-up was presented from the ACUITY trial
17). Patients (n  13,819) with moderate- and high-risk
CS were randomized to heparin (unfractionated or enoxapa-
in) plus glycoprotein IIb/IIIa inhibition, bivalirudin plus
lycoprotein IIb/IIIa inhibition, or bivalirudin monotherapy
plus provisional glycoprotein IIb/IIIa inhibition). Stone et al.
17) showed that bivalirudin is an acceptable substitute for
ither unfractionated heparin or enoxaparin. Moreover, major
leeding complications had a significant, independent, adverse
mpact on 30-day outcomes, including mortality, and treat-
ent with bivalirudin was an independent predictor of free-
om from major bleeding (18).
At 1 year, approximately 98% of all ACUITY patients
ere available for follow-up, and investigators looked at the
djudicated end points of composite ischemia and stent
hrombosis (19). There was no significant difference among
he arms in terms of the composite ischemia end point
Table 4); however, interestingly, the lowest number of
eaths were in the bivalirudin-alone arm and there appeared
o be a slight separation of the curves at 1 year, trending in
ACUITY: Ischemic Composite End Point (Death,Unplanned Revascularization for Ischemia), S en
Table 4 ACUITY: Ischemic Composite End PUnplanned Revascularization for Isc
UFH/Enoxaparin 
GP IIb/IIIa
(n  4,516)
Ischemic composite end point
30 days 7.4%
1 yr 16.3%
Stent thrombosis
30 days 1.3%
1 yr 1.0%
Morality
30 days 1.4%
1 yr 4.4%p1  Bivalirudin  GPI versus UFH/Enoxaparin  GPI; p2  Bivalirudin alone
GP  glycoprotein; GPI  glycoprotein inhibitor; UFH  unfractioned hepaavor of bivalirudin monotherapy. The results suggest a
elationship between iatrogenic bleeding complications and
ubsequent mortality in patients with ACS. Calling this an
important message,” Dr. Harrington said preventing bleed-
ng early on in the setting of ACS “may carry important
rognostic implications.”
The MERLIN-TIMI 36 study provided new long-term
afety data on ranolazine in a high-risk population of
atients (n  6,560) (20). Individuals randomized to active
herapy received 200 mg of ranolazine intravenously for 1 h,
ollowed by an 80-mg/h infusion for up to 96 h. This group
hen took 1,000 mg of oral ranolazine twice daily for
pproximately 12 months. The control group underwent
ntravenous and oral placebo therapy.
Although the MERLIN-TIMI 36 study did not meet its
rimary end point of reducing cardiovascular death, myocardial
nfarction (MI), or recurrent ischemia compared with placebo,
here was a significant reduction in recurrent ischemia (p 
.03) as well as a reduction in the percentage of patients with
orsening angina at 12 months in the ranolazine group
ompared with the placebo arm (p  0.023) (Fig 1). The
vidence suggests antianginal efficacy of ranolazine in a much
roader population than ever studied before with this agent.
Dr. Harrington noted, “I was a great skeptic of ranola-
ine, which had not been well studied except in trials largely
valuating changes in exercise testing over time.” Now, he
aid, there is a new option for patients who don’t respond—or
top responding—to standard antianginal agents or patients
hose blood pressure is too low to increase medication dosage.
ndeed, the evidence suggests ranolazine may be most
ffective in patients with refractory angina. Finally, Dr.
arrington said, there was no clinically important QT
rolongation with this agent compared with placebo. In
act, there were fewer clinically significant arrhythmias on
olter monitoring in the patients on chronic ranolazine
73.7% vs. 83.1%; p  0.001).
In discussing the ARISE (Aggressive Reduction of In-
ammation Stops Events) trial, Dr. Harrington called the
esults “a big disappointment” (21). It was a double-blind,
lacebo-controlled trial of 6,145 high-risk patients with a
ombosis, and Mortality
(Death, MI,
a), Stent Thrombosis, and Mortality
lirudin 
IIb/IIIa
4,502)
Bivalirudin
Alone
(n  4,521) p1 Value p2 Value
7.8% 7.9% 0.36 0.38
16.5% 16.4% 0.34 0.31
1.6% 1.3% 0.39 0.97
0.8% 0.5% 0.78 0.52
1.6% 1.6% 0.53 0.39
4.2% 3.8% 0.93 0.66MI,t Thr
oint
hemi
Biva
GP
(n versus UFH/Enoxaparin  GPI.
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August 21, 2007:C2–31 ACC 2007 Annual Session Highlightsecent ACS. Patients were randomized to receive a probucol
nalog (succinobucol or AGI-1067) or placebo in addition
o standard care. The primary end point was time to first
ncidence of any centrally adjudicated events: cardiovascular
ortality, resuscitated cardiac arrest, MI, stroke, use of
oronary revascularization, or hospitalization for unstable
ngina.
Because of the agent’s antioxidant/anti-inflammatory ef-
ects, it was hoped that by focusing on inflammation the
rug might “really change the paradigm of treating the acute
schemic heart,” said Dr. Harrington. However, there was
o difference in the primary end point (17.2% vs. 17.3% for
lacebo; p  0.985). Although there were some benefits in
he treatment group, such as a significant reduction in
ew-onset diabetes mellitus (p  0.0001) and improved
asting glucose (p  0.0001), some individual components
f the ARISE primary end point favored placebo, such as
ncidence of unstable angina and revascularization. More-
ver, LDL increased and HDL decreased with active
herapy.
Despite the availability of numerous antithrombotic ther-
pies, adverse events after percutaneous coronary interven-
ion (PCI), such as late stent thrombosis, are still a major
oncern. Researchers at the University of Kentucky, Gill
14% ↓
21.8
13.9
4.2
5.9‡
23.5*
16.1†
0
5
10
15
20
25
23% ↓
%
CV death/MI/RI Recurrent ischemia Worsening angina* 
Figure 1 Assessment of Antianginal
Effects in the MERLIN-TIMI 36 Trial
Selected efficacy end points in the MERLIN-TIMI 36 trial. Based on Kaplan-
Meier cumulative incidence (%) at 12 months. Primary end point: cardiovascu-
lar (CV) death/myocardial infarction (MI)/recurrent ischemia (RI). *p  0.11;
†p  0.03; ‡p  0.023. Blue bars  ranolazine (n  3,279); yellow bars 
placebo (n  3,281).
TRA-PCI Cohort Results at 60 Days of an Oral S
Table 5 TRA-PCI Cohort Results at 60 Days
Placebo
(n  151)
All
(n  422
TIMI major/minor* 5 (3.3%) 12 (2.8%
Non–TIMI bleeding 48 (32%) 173 (41%
Death/MACE* 13 (8.6%) 25 (5.9%
MI 11 (7.3%) 11 (7.3%
*Primary end point (safety); secondary end point (efficacy).
MACEmajor adverse cardiac event; MImyocardial infarction; PCI pe
Infarction; TRA  thrombin receptor antagonist.eart Institute, and Duke Clinical Research Institute led a
hase II, randomized, double-blind, placebo-controlled trial
o evaluate a potent new oral thrombin receptor antagonist
TRA), SCH 530348, for reducing PCI complications (22).
The TRA-PCI study randomized 1,030 patients in a 3:1
atio to a 10-, 20-, or 40-mg loading dose of SCH 530348
r placebo. Of the total patient population, 573 underwent
CI (primary cohort) whereas 75 underwent coronary artery
ypass graft surgery and 382 were managed medically.
atients undergoing PCI (primary cohort) were further
andomized to a 0.5-, 1.0-, or 2.5-mg daily maintenance
ose of SCH 530348 or placebo (depending on loading
herapy) for 60 days. Patients also received other standard
herapies, including aspirin, clopidogrel, and an antithrom-
in. The primary safety end point was Thrombolysis In
yocardial Infarction (TIMI) major or minor bleeding at
0 days in the PCI cohort. Secondary end points included
he composite of death and major adverse cardiac events
MACE) at 60 days, again in the PCI cohort.
Overall, TRA treatment reduced adverse event rates in
he study population without an increase in bleeding risk
Table 5). Major TIMI bleeding was reduced in the
ow-dose cohorts of TRA patients as compared with pla-
ebo (1.6% vs. 3.3%). The highest-dose TRA-treated pop-
lations fared best in overall death or major adverse events
ompared with placebo (4.6% vs. 8.6%) as well as heart
ttack risk (3.5% vs. 7.3%). Although not statistically
ignificant, this new TRA led to a 32% overall reduction in
eath/MACE and a 41% overall reduction in MI.
A key TRA-PCI substudy evaluated percent inhibition of
latelet aggregation. A 40-mg loading dose of SCH 530348
chieved80% inhibition of platelet aggregation in 1 to 2 h
n 68% to 96% of subjects, and 1- and 2.5-mg maintenance
oses led to sustained 80% inhibition of platelet aggrega-
ion at 30 and 60 days in all subjects.
An expanding body of evidence continues to build on the
elationship between bleeding and outcome. Dr. Steve
teinhubl and others have shown that inflammatory mark-
rs may be the pivotal link (23,24). At ACC.07, Jozic et al.
25) presented results from the ACUITY inflammatory
iomarker substudy. They found that major bleeding events
n patients experiencing an ACS are associated with striking
ncreases in inflammation as measured by change in high-
ive TRA
Oral Selective TRA
SCH 530348
10 mg
(n  129)
20 mg
(n  120)
40 mg
(n  173)
2 (1.6%) 3 (2.5%) 7 (4.0%)
47 (36%) 52 (43%) 74 (43%)
11 (8.5%) 6 (5.0%) 8 (4.6%)
7 (5.4%) 5 (4.2%) 6 (3.5%)elect
of an
)
)
)
)
)rcutaneous coronary intervention; TIMI Thrombolysis In Myocardial
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ACC 2007 Annual Session Highlights August 21, 2007:C2–31ensitivity C-reactive protein from admission to discharge.
he heightened inflammatory response with bleeding may
elp explain increases in long-term thrombotic events in
his population.
In concluding the non–ST-segment elevation ACS high-
ights, Dr. Harrington said, “Finally, a really interesting
heme throughout the last few days: monocyte activation as
erhaps one of the key pathogenic underpinnings of acute
oronary syndromes.”
uestion and Answer
r. Tuzcu: This meeting had more studies than ever, I
hink, presenting so-called negative results or results that
id not meet the primary end point. Having said that, even
he ARISE study results suggest some hope that researchers
ontinue investigating this approach. Certainly the ARISE
ata were far from conclusive; there were a lot of conflicting
ata. In ARISE, they had an increase in LDL and a
owering of HDL, but despite that they did not have
ncreased hard end points.
r. Harrington: ARISE is a tough trial to interpret.
verall, it did not meet its primary end points, but clearly it
s critically important in this format to talk about trials that
re neutral or negative. We do learn a lot.
What troubles me about ARISE is maybe there is a
ypothesis there that some of the events were more favor-
ble with treatment, but at the same time there were a fair
umber of events, such as heart failure, revascularization,
nd recurrent ischemia, that did not look so favorable for the
tudy drug. This split between improvement in glucose and
he deleterious effect on LDL all seems to me to kind of
ash to the middle of not working.
r. Stein: You can’t pick and choose the effects that come
rom this drug (succinobucol).
r. Harrington: Jim, that’s a good way to look at it. There
ere some good effects and bad effects. As Murat suggested,
o I think there is enough there for a hypothesis if the
nvestigators wanted to go forward? Sure, but we have to
nterpret it with what we have right now.
r. DeMaria: With some exceptions, the negative trials
on’t seem to get simultaneous publication. They dwindle
way a bit more, don’t they?
r. Harrington: That’s probably an issue for the journals as
ell as for the investigators. All of us, perhaps at times, lose
little interest when a study is not positive, but your
essage is that it’s critically important that we get this
nformation out because there is an enormous amount to
earn, probably more to learn from a failed trial than there is
o a positive trial.
r. Conti: The important message I take from MERLIN is
hat it was given to the sickest of our patients, those with
CS. It was given intravenously in fairly high doses, but it
idn’t produce any of the problems we were concerned
bout: the QT prolongation, arrhythmias, and so forth.
The other point that I took from that trial, granted it’s
subanalysis, but if anyone wants to continue looking at this drug in acute coronary syndromes, you want to pick
he individuals who are TIMI risk score 4 and greater
ecause that particular group seemed to do much better
n terms of decreased end points than those who were less
han TIMI 4.
r. Harrington: Your first point is incredibly important.
ere was a drug from one of the first new classes of agents
o treat angina in many, many years. A lot of us were quite
oncerned about this issue of QT prolongation. In MER-
IN, as you say, if we gave it to the sickest group of patients,
rst intravenously, then orally, and we follow them very
arefully and use Holter monitoring—we were very rigorous
bout this—that might be worth studying. To me, that was
ne of the most important findings to come out of that
articular trial; this QT issue seems to be largely resolved.
T-Segment Elevation Myocardial Infarction (STEMI)
yocardial damage caused by ischemia and reperfusion
imits current reperfusion strategies for patients with acute
TEMI, and reducing infarct size remains an elusive target.
t the i2 Summit, investigators presented data on a novel
rotein kinase C inhibitor (KAI-9803), which has been
hown in animal models to reduce infarct size, enhance
ecovery of left ventricular (LV) contractility, and improve
icrovascular function when administered before reperfu-
ion (26,27). In an exploratory, first-in-human study, the
gent demonstrated a favorable impact on multiple bio-
arkers of reperfusion success, including creatine kinase-
yocardial band area under the curve and ST-segment
ecovery area under the curve.
Stem cells remain a big news item, although many of the
urrent studies are returning to the basics, trying to under-
tand the implications of the electrical abnormalities of what
appens when you try to implant cells in the infarcted
yocardium.
Quality of care clearly remains an important issue and a
ey initiative of the American College of Cardiology. In an
2 Summit session on the National Cardiovascular Data
egistry (NCDR), Ralph Brindis, MD, FACC, Chief
edical Officer of the ACC-NCDR, and a panel of experts
ummarized current trends for clinical practice and patient
utcomes. The CathPCI Registry now has 890 participants
nd 4.5 million patient records. There have been 19 pub-
ished manuscripts: 2 are in press and 17 are in develop-
ent. (Six abstracts were presented at ACC.07.)
Nearly 1 decade after initiating the CathPCI registry, the
ollege has 3 new projects that were launched in the last
ear: an implantable cardioverter-defibrillator (ICD) regis-
ry (1,450 hospitals are enrolled with 120,000 patient
ecords now in the registry), the CARE registry (with more
han 85 participating centers) for carotid stenting and
arotid endarterectomy data, and the ACTION registry
already with more than 100 participating centers and
nother 450 centers expressing interest), which is an ACS
egistry representing the merging of 2 drug company regis-
ries. In the near future there will be an ambulatory care
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August 21, 2007:C2–31 ACC 2007 Annual Session Highlightsegistry related to CHD, the IC3 coronary artery disease
CAD) registry, and a longitudinal ICD registry; plus, the
CC Foundation is looking for funding to develop a
ong-term registry looking at PCI outcomes (the Achieve
egistry). In feasibility and business model planning there
re 2 other possible projects: an imaging registry and a
ongenital heart disease registry.
Door-to-balloon times were highlighted during the week,
nd important progress is being made. Among the 580
CDR participating hospitals, there was a marked nation-
ide improvement in door-to-balloon time in 2004 with
ontinued modest improvement through the first quarter of
007 (Fig. 2). Two external influences may have positively
ffected this performance metric in 2004. The first was the
ublication of updated STEMI guidelines (28). Recom-
ended door-to-balloon time in the 1999 guidelines was
0  30 min; in the updated document, chaired by Elliot
ntman, MD, FACC, the recommendation was tightened
o 0 to 90 min based on overwhelming evidence favoring a
oor-to-balloon time of 90 min or less. The second external
orce that could have influenced the marked improvement in
oor-to-balloon time in 2004 among NCDR participating
enters was public reporting of quality data relating to the
oint Commission on Accreditation of Healthcare Organi-
ations and the Centers for Medicare & Medicaid Services
nnouncement of using door-to-balloon time as a core
easure of quality. Said Dr. Harrington, “As public report-
ng of these data were announced, in fact, our door-to-balloon
ime started to get better.” In the last quarter of 2006, there was
more modest increase in slope to this performance metric
hat corresponded to the release of the alliance door-to-balloon
nitiative. It will be interesting to continue tracking these
umbers now that there are more than 800 centers participat-
ng in the door-to-balloon initiative.
Figure 2 Trend for DBT for 586 National
Cardiovascular Data Registry Hospitals
Data are based on the hospital’s ability to perform percutaneous coronary
intervention (PCI) in their composite patients in 90 min. DBT  door-to-
balloon time.oDr. Harrington cited several lessons regarding patients with
ardiogenic shock, the leading cause of death among hos-
italized patients with acute myocardial infarction. At
CC.07, Singh et al. (29) presented an 11-year follow-up
f the original GUSTO I (Global Utilization of Streptoki-
ase and tPA for Ocluded Arteries-I) SHOCK (Should We
mergently Revascularize Occluded Coronaries for Cardio-
enic Shock?) cohort. Of the 22,883 U.S. patients with
ata, shock occurred in 1,891 (8.3%); 953 (50.4%) of these
atients survived 30 days; and 527 (27.8%) survived 11
ears. In comparing the data to those patients without
hock, annual mortality was 2% to 4% after the first year
egardless of whether patients did or did not have shock.
hus, although the mortality of shock is very high within
he first 30 days, after 1 year, annual mortality approximates
atients without shock. “That suggests that the intensive
fforts underway to improve the early care of the shock
atient are worthwhile,” said Dr. Harrington.
Experimental data suggest that high levels of nitric oxide
ay play a role in the genesis and persistence of cardiogenic
hock. The TRIUMPH (Tilarginine Acetate Injection in a
andomized International Study in Unstable MI Patients
ith Cardiogenic Shock) trial tested the effect of nitric oxide
ynthase inhibition with tilarginine on mortality attributable
o persistent cardiogenic shock complicating MI despite an
pen infarct artery (30). In this international study of nearly
00 patients, tilarginine, 1-mg/kg bolus and 5-h infusion,
id not reduce mortality rates (31). (This was a negative trial
hat was published simultaneously.)
In a small study from the Texas Heart Institute, investi-
ators evaluated the TandemHeart, a percutaneously placed
ontinuous-flow left ventricular assist device (PVAD) capa-
le of complete hemodynamic support (32). At ACC.07,
hey presented 1-year outcomes in cardiogenic shock pa-
ients receiving PVAD assistance after failure of intra-aortic
alloon counterpulsation and pressor support. The PVAD
eversed the terminal hemodynamic compromise in patients
ith severe refractory cardiogenic shock, even in patients
ndergoing active resuscitation; 1-year mortality was 56%.
Even amongst patients who were being resuscitated, again
he message is that if you survive that initial insult, there is
easonable 1-year mortality,” said Dr. Harrington.
In wrapping up the STEMI highlights, Dr. Harrington
eviewed the results of the COURAGE (Clinical Outcomes
tilizing Revascularization and Aggressive Drug Evalua-
ion) trial, which enrolled 2,287 patients with stable CAD
ho were randomized to PCI plus optimal medical therapy
n  1,149) or optimal medical therapy alone (n  1,138)
33). Both groups received intensive lifestyle intervention.
he primary end point was death or nonfatal MI during a
ean follow-up of 4.6 years. All patients had single or
ultivessel disease, defined as at least 70% visual proximal
tenosis of a major epicardial coronary, and Canadian
ardiovascular Society class I to III angina, as well as
bjective evidence of ischemia at baseline.
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ACC 2007 Annual Session Highlights August 21, 2007:C2–31For both groups, optimal medical therapy was “intensive,
uideline-driven” therapy, including aspirin and/or clopi-
ogrel; a statin; angiotensin-converting enzyme inhibitor or
ngiotensin receptor blocker; beta-blocker; calcium channel
locker; and a nitrate. Lifestyle interventions involved
moking cessation, exercise programs, nutrition counseling,
nd weight control where needed.
The addition of PCI to optimal medical therapy (OMT)
id not significantly improve any end points measured in
he COURAGE trial, including the primary end point of
eath or MI (19.0% for PCI vs. 18.5% for OMT; p 0.62).
nexpectedly, angina improved almost as much in the
MT group as it did in the PCI group, and although there
as a significant difference in favor of PCI at 1 and 3 years
p  0.001 and p  0.02, respectively), this difference
issipated by 5 years (Table 6). The findings reinforce
urrent guidelines that recommend deferring PCI in stable
ngina patients treated with intensive OMT.
Dr. Harrington wondered how big the population is in
linical practice similar to those enrolled in the COURAGE
rial. “My sense is that if we look at the registries, we look
t the clinical trials, about 60% of our patients undergoing
ntervention fall into the category of acute or urgent and
0% nonacute, nonurgent,” he said. What percentage of
hese patients would fit the criteria used to enroll patients in
he COURAGE trial?
“My back-of-the-envelope estimation, although I’d like
o see more research done on this, is probably half or so of
hose nonurgent interventions might meet the COURAGE
riteria.”
uestion and Answer
r. Knopf: It’s encouraging that patients who have chronic
table angina can be treated medically, but you do have to
reface that with the fact that all of these patients under-
ent cardiac catheterization before randomization. That’s a
ery important point that needs to be highlighted. So, these
atients were a little more stable and did not have high-risk
natomy that would warrant interventions.
If you look at the total patients who were screened, about
% of this population was enrolled. Certainly angioplasty is
ppropriate for primary intervention, certainly appropriate
or acute coronary syndromes, and that is still the majority
f the patients that we take care of in the interventional
reedom From Angina Duringong-Term Follow-Up in the COURAGE Trial
Table 6 Freedom From Angina DuringLong-Term Follow-Up in the COURAGE Trial
PCI  OMT OMT
Baseline 12% 13%
1 yr 66% 58%*
3 yrs 72% 67%†
5 yrs 74% 72%
p  0.001; †p  0.02.
OMT  optimal medical therapy; PCI  percutaneous coronary intervention.orld. pr. Starling: I’m not an interventional cardiologist; I’m a
linical heart failure cardiologist. Help me with the patient
ith chronic stable angina who maybe underwent catheter-
zation 5 or 6 years ago or who presents now without an
cute coronary syndrome. How are we going to stratify these
atients and make decisions? Are you suggesting, Bill, that
hey all need to undergo angiography? How are we going to
ut that in balance with the findings from COURAGE?
r. Knopf: Clearly, if you follow the COURAGE protocol,
hey would all undergo cardiac catheterization, but I’m not
dvocating that. In the general patient population, patients
ith chronic symptoms and with a reasonable quality of life
re perfectly fine on medical therapy. Those patients can be
tratified as you would normally and as the COURAGE
nvestigators did. They excluded those patients who had
arkedly abnormal stress tests, 1 or more millimeters’
T-segment deviation on electrocardiogram, early positive
tress tests, hypotension, things of that nature. Those
atients were not included in the trial, so there are numer-
us patients you could restratify based on stress test results.
r. Harrington: The key message here is the same one
ddressed in the chronic stable angina guidelines: you can go
o catheterization if the patient has refractory symptoms, a
igh-risk stress test, you’re uncertain of the diagnosis, or
here is evidence of heart failure or hemodynamic instability.
hat COURAGE really tells us is this: if you’re being
anaged well with medical therapy, you’re being managed
ell.
I don’t think the COURAGE investigators are telling us
hat these are two competing strategies. They’re comple-
entary strategies and what the COURAGE results ought
o get us to do is talk to the patients. Make sure we’re
onsidering their values, their preferences; what’s the strat-
gy for that particular patient that’s going to fit the best with
hat they want to do?
r. DeMaria: The COURAGE trial has the limitations of
very randomized clinical trial: you can’t get everybody into
he trial. You need a registry for that kind of thing. Also, it’s
n intention-to-treat analysis, so there were several cross-
vers to the other therapy; but, to be fair, there also were
everal re-do’s of revascularizations. The strength of this
rial in my view is the medical management. As far as I
now, this is the only protocol-driven trial with optimum
edical management in both arms, and we have to look at
hat aspect of it.
r. Harrington: I think COURAGE was a terrific clinical
rial and the investigators should be complimented. They
id a superb job, and the medical therapy in this trial is truly
ptimal. I don’t think what they’re saying is that we should
e going down one path or another. It’s how do we use these
pproaches? But the pivotal underpinning here is OMT,
nd they did a superb job.
r. DeMaria:We need some controversy here, so I’m going
o disagree a little. The ascertainment bias is an important
uestion. You enroll at 50 centers for 5 years to get 3,000
atients; there are a whole lot of unenrolled patients out
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August 21, 2007:C2–31 ACC 2007 Annual Session Highlightshere. I do stand in awe of their ability to do maximal
edical therapy. Their compliance rate was extraordinary.
’m not sure how successful I’d be.
That being said, extrapolating on the findings here is the
dea that patients who ought to be considered for interven-
ion should have failed maximum medical therapy. I don’t
elieve, by and large, that’s the practice in the U.S. today.
ore often, patients get some medical therapy. If you know
hey can’t alpine ski because they get a little bit of angina,
ven if it’s single-vessel disease, they’re apt to be treated
nterventionally. I do think the COURAGE results will
ave an impact to some extent and reduce the number of
nterventions being done.
nnovation in Intervention: i2 Summit
n its second year, the Innovation and Intervention or i2
ummit continued to build on its success with excellent
rogramming involving some of the world’s leading inter-
entionalists. There were 789 abstract submissions to the
007 i2 Summit, including 17 late-breaking clinical trials
of 29 submitted) and 225 other accepted abstracts for
resentations.
A highlight of the i2 meeting is live cases, and in 2007
hese real-time demonstrations included more international
ctivity. The cases were transmitted to New Orleans from 8
ites, including Japan, the Netherlands, Canada, and several
.S. sites. It was a great opportunity to see master inter-
entionalists work live on complex, everyday practical issues
n interventional cardiology. Moreover, rather than showing
set way to manage a case, the live presentations demon-
trated how the physician thinks through a procedure and
ow strategy changes when a problem is encountered.
For example, in 1 live demonstration, a stent became
tuck and the interventional cardiologists had to decide
mmediately which technique to use to engage the guiding
atheter to force the stent down. The session moderator,
lan Yeung, MD, FACC, Director of Interventional Car-
iology and Division Chief at Stanford University Medical
enter, noted that the ad-hoc aspect of the case would likely
ot be mentioned in a publication describing the procedure.
Dr. Knopf co-chaired the i2 Summit with Barry F.
retsky, MD, FACC, and David R. Holmes, Jr., MD,
ACC. The 2007 sessions were in the heart of the conven-
ion center and in the heart of the ACC meeting. In a
aturday morning session before the opening of ACC.07,
he i2 Summit highlighted issues germane to general car-
iologists as well as interventionalists, dealing with topics
uch as late stent thrombosis, carotid stenting versus sur-
ery, multivessel disease in diabetics, and more, which
ngendered interesting debate and cross-discipline discus-
ion with colleagues in cardiovascular surgery and vascular
urgery.
This year’s demonstrations included new or improved tech-
iques for chronic total occlusion angioplasty from Japanese
nvestigators who are masters at this type of technique. Dr. folmes demonstrated how to do a closure of a paravalvular
itral prothesis. Complex interventional cases included left
ain and peripheral vascular interventions.
An emerging technologies track emphasized the early
ature of the data presented, making it clear, in some cases,
hat the science is not necessarily ready for even phase I
rials yet. One presentation featured preliminary results of
uropean and U.S. trials of the Rheos Baroreflex (CVRx,
aple Grove, Minnesota), an implantable device for the
reatment of resistant hypertension (34). By modulating the
aroreceptors in the carotid sinus, the brain perceives
ncreased afferent signaling as an increase in blood pressure
hat needs to be corrected. In early trials, the Rheos device
ignificantly reduced both systolic and diastolic blood pres-
ure. In an evaluation of long-term effectiveness, the device
eems to have had a profound and durable effect in the 49
atients implanted worldwide (as of March 2007) with 822
atient-months of follow-up.
Another first-in-human study evaluated a new absorbable
tent. Currently available drug-eluting stents (DES) dra-
atically reduce restenosis rates after PCI compared with
are-metal stents (BMS), but there are drawbacks to both
ypes of stents. Any permanent metallic implant may impair
oronary imaging with magnetic resonance imaging or CT,
an hinder surgical revascularization, prevent positive re-
odeling, and (in the case of DES placement) predispose
he vessel to late stent thrombosis. At the 2007 i2 Summit,
erruys et al. (35) reported the results of a study using a
ovel absorbable stent with controlled-release drug delivery.
nce the stent degrades completely, only the healed natural
essel remains.
According to principal investigator Patrick W. Serruys,
D, FACC, the scaffolding effect of any stent is needed for
nly 3 to 6 months to prevent constrictive vascular remod-
ling after dilation. But the traditional metal cage, which is
ow he describes metal stents, remains long after this
eriod. The bioabsorptive properties of the new stent appear
o allow late expansive luminal and vessel remodeling that is
ot hindered as it is now with metal stents. The newer
oating used on the stent also may minimize chronic
nflammation seen with current agents and may reduce the
eed for long-term dual antiplatelet therapy.
The biodegradable stent was placed in a single de novo
oronary artery lesion in 30 patients. At 30 days, device
uccess was 93.5%, and procedural success was 100% with
o MACE or stent thrombosis. At 6 months, rates of
ACE continued to be low: 1 patient (3.3%) had a
on–Q-wave MI. Angiographic results, available for 26
atients at the time of the ACC meeting, showed good
esults (Table 7) with late loss (0.44 mm) in between that
eported in standard DES trials and BMS studies. Although
eointimal hyperplasia was very much under control, some
ate recoil of the stent was evident, which may be due in part
o stent design. According to Dr. Serruys, a second iteration
f the stent appears to be much stronger in terms of radial
orce and scaffolding properties.
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number of studies sought to better understand late stent
hrombosis. Imaging data suggest that late acquired incom-
lete stent apposition is evident in a high percentage of
atients who develop late stent thrombosis. Second, patients
ith acute MI who receive DES seem to have a greater
ncidence of late stent thrombosis. Investigators are trying to
etermine which patients are at highest risk for late throm-
osis in an effort to reduce the occurrence of this often-
minous outcome. Until then, it is encouraging that the
ncidence of late stent thrombosis is still very low.
The data from the MATRIX trial was particularly en-
ouraging. It is a prospective, single-arm study, initiated in
004, to evaluate the impact of sirolimus-eluting stents
SES) in a consecutive ”real-world” population. The late
tent thrombosis rate at 2 years was 1.1% after off-label use
f the stents (36). In 12,395 patients from western Denmark
eceiving either a DES or BMS, there was no significant
ifference in mortality at approximately 15-month
ollow-up (p  0.29) and a similar low rate of late stent
hrombosis at 12 months (0.6% annually) (37). However,
etween 12 and 15 months, there was a small but significant
xcess of definite stent thrombosis and MI in the DES
roup (Fig. 3).
Two major stent trials were reported at ACC.07, including
onger-term follow-up of the ENDEAVOR III (Randomized
omparison of Zotarolimus-Eluting and Sirolimus-Eluting
tents in Patients With Coronary Artery Disease) trial (38).
he single-blinded study compared the second-generation
ndeavor zotarolimus-eluting stent (n  316) with SES
lacement (n  110). At 24 months, no late stent throm-
osis was evident in the Endeavor group. Finally, SPIRIT
II (A Randomized Trial of Anticoagulants Versus Aspirin
BSORB: Angiographic ResultsPer-Treatment Ev luable)
Table 7 ABSORB: Angiographic Results(Per-Treatment Evaluable)
Lesions (n  26)
Pre-procedure*
LL (mm) 8.66
RVD (mm) 2.78
MLD (mm) 1.10
DS (%) 59.0
In-stent acute gain (mm) 1.24
Post-procedure
In-stent MLD (mm) 2.33
In-stent DS (%) 16.0
6-month follow-up
In-stent MLD (mm) 1.88
In-stent DS (%) 27.0
In-stent late loss (mm) 0.44
In-stent ABR (%) 11.5†
Matched view analysis—for 1 patient, no matched views. †Matched view analysis—respective
atients: LL: 1.6 mm, 50% DS, no symptoms / LL: 0.31mm, 50% DS, angina at rest / LL: 0.88mm,
5% DS, no symptoms.
ABR  angiographic binary restenosis; DS  diameter stenosis; LL  lesion length; MLD 
inimal lumen diameter; RVD  reference vessel diameter.fter Cerebral Ischemia of Presumed Arterial Origin)ompared everolimus-eluting stents with first-generation
axus stents (Boston Scientific, Natick, Massachusetts)
39). For the primary end point of in-segment late loss at 8
onths, the XIENCE stent (Abbott Laboratories, Abbott
ark, Illinois) showed a p value of 0.0001 for noninferi-
rity compared with the Taxus stent and a p value of 0.004
or superiority (Fig. 4). The newer stent was associated with
ower rates of target lesion revascularization (p  0.004)
hrough 270 days, which contributed to a significant 44%
eduction in MACE (p  0.028) (Fig. 5).
uestion and Answer
r. Conti: Bill, what’s your take on the bioabsorbable
tents? I was impressed with Patrick Serruys’ data, but it’s
bviously preliminary. Where do you think that’s heading?
r. Knopf: They have 26 patients and only 6 months’
ollow-up, but the encouraging news was the low rate of
arget lesion revascularization at 6 months and no stent
hrombosis, suggesting that it’s certainly safe and well
olerated. The late loss of 0.44 mm means there seems to be
Figure 3 Definite ST and MI After
Implantation of DES or BMS in Western Denmark
(A) Definite stent thrombosis (ST) and (B) myocardial infarction (MI).
BMS  bare-metal stent(s); DES  drug-eluting stent(s); RR  risk ratio.
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August 21, 2007:C2–31 ACC 2007 Annual Session Highlightsppropriate healing of the vessel, which is important. There
as some late-acquired stent apposition observed with
ntravascular ultrasound and that is of some concern, but
ntuitively if you can design something that is completely
ioabsorbable there is certainly some interest and long term
e will have to see if the results are favorable. I think it
ould be.
r. DeMaria: Not having heard those trials presented, one
f the questions I have relates to the length of antiplatelet
herapy in them. What were they doing?
r. Knopf: I can’t answer that question about the specific
rials, but the recommendation now is to give aspirin and
lopidogrel for 12 months. There was one trial that was very
nteresting; it was small and called the Low Responsiveness
o Clopidogrel and Sirolimus- or Paclitaxel-Eluting Stent
hrombosis, or RE-CLOSE trial (40). The investigators
emonstrated that people who were nonresponders to clo-
idogrel seemed to have a greater incidence of late stent
hrombosis.
This raises the question: Are we giving the right anti-
latelet strategy? And, if we are, how are we monitoring
hose patients? Should we be monitoring them more than
e are? Obviously we’re not really monitoring patients at all
or this; we’re empirically giving these drugs. Would mon-
toring for antiplatelet effectiveness impact things? How-
ver, from the western Denmark trial anyway, the incidence
f late stent thrombosis at 12 months was no different
hether patients were on or off clopidogrel (37).
r. Tuzcu: Before you finish, can I ask you a question: when
ou are back to your practice in Atlanta after this meeting,
hat are you going to change as far as your use of DES?
r. Knopf: Right now there is a trend to be more judicious
bout using DES. We learned that in patients with acute
I, perhaps BMS are better for the long term, although you
o sacrifice the restenosis benefit of DES. Also, for patients
ith large vessels or short lesions where the restenosis rate
s low, those patients definitely can benefit from a BMS and
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
-1 -0.5 0 0.5 1 1.5 2 2.5 3
In-segment Late Loss (mm)
TAXUS: 0.28 ± 0.48 (n=134)
PNI < 0.0001
PSUP = 0.004
XIENCE V: 0.14 ± 0.41 (n=301)
%
 o
f 
L
es
io
n
s
Figure 4 In-Segment Late Loss at 8 Months*
(Primary End Point) of the SPIRIT III Trial
*Follow-up window  28 days.ot a DES. Therefore, we’re beginning to categorize pa-ients who might not necessarily need a DES and that’s
mportant. At this moment, the overall market penetration
s back up to about 30% for BMS versus 70% for DES in the
.S.
alvular Heart Disease
here were 67 presentations related to valvular heart disease
t the ACC.07 Scientific Session, including insights into
he mechanisms and treatment of aortic stenosis (AS) and
he results of studies evaluating percutaneous approaches to
alvular repair or replacement. These presentations were
elected from a total of 175 abstracts submitted to the
rogram Committee. Importantly, a number of presenta-
ions at the i2 Summit related to valvular heart disease.
Dr. Kapadia is an interventional cardiologist at the
leveland Clinic and the presenter of valvular heart disease
ighlights from ACC.07 and the i2 Summit. He noted that
ome of the most important information was related to the
rogression of AS with multiple laboratories reporting
ifferent mechanisms of AS progression, including LDL-
elated mechanisms and cytokine-, adipokine-, and even
arathormone-related mechanisms (41–43). (Parathormone
s a hormone made by the parathyroid gland.)
Other unique mechanisms for AS involve matrix-Gla
roteins in bone that increase mineralization (44) and
lpha2-HS glycoprotein, also known as fetuin-A, which is a
lasma protein displaying high-affinity interaction with
alcium phosphate, by which ectopic vascular calcification is
revented (45). All of these studies suggest that different
echanisms affect different populations, such that an elderly
opulation may have different mechanisms for AS than a
ounger population. Plus, there may be differences in the
ay patients with atherosclerosis respond to different kinds
f progression of calcification in AS.
One trial, highlighted by Dr. Kapadia, evaluated the role
f oxidized low-density lipoprotein (ox-LDL) in AS. Con-
idering that ox-LDL is a powerful inflammatory factor in
therosclerotic plaques, several studies have suggested that
alcified AS is related to an atherosclerotic-like process. The
Figure 5 MACE and TLR Through 270 ( 14) Days
in the SPIRIT III Trial
Blue bars  XIENCE V (n  658); yellow bars  TAXUS (n  322). ID  isch-
emia-driven; MACE  major adverse cardiac events; NID  nonischemia-driven;
TLR  target lesion revascularization.
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ACC 2007 Annual Session Highlights August 21, 2007:C2–31bjective of the study presented at ACC.07 by a team of
anadian investigators in Quebec was to examine the
ssociation between: 1) the plasma metabolic profile and the
resence of ox-LDL within the aortic valve; and 2) the
x-LDL accumulation and the degree of valvular inflam-
ation (41). There was a significant association between the
ercentage of small-size LDL particles in the plasma and
x-LDL score within the valve (p  0.03), whereas total
holesterol and LDL levels were not associated with ox-
DL. Patients with the highest ox-LDL scores (on a scale
f 0 to 3) had a greater percentage of small-size LDL
articles compared with those with a score of 0. In turn,
alves with higher ox-LDL content were associated with
ncreased numbers of leucocytes (p 0.03), macrophages (p
0.008), and T cells (p  0.03) as well as with increased
xpression of tumor necrosis factor-alpha (p  0.002).
inally, patients with an ox-LDL score of 3 also had a much
ore rapid preoperative hemodynamic progression of their
tenosis as measured by the annualized progression rate of
eak transvalvular pressure gradient (p  0.04).
Another important topic highlighted during this meeting
as patient prosthesis mismatch (PPM) with mitral valve
eplacement (MVR). There are several studies in which
esearchers have examined PPM in patients after aortic
alve replacement, but little retrospective data exist in
atients who have undergone MVR. Two studies presented
s posters at ACC.07 evaluated patients with moderate
1.2 cm2/m2) or severe (0.9 cm2/m2) PPM and out-
omes for these patients compared with those with no or
esser degrees of PPM (clinically insignificant PPM: 1.2
m2/m2) after MVR (46,47). Both had the same message:
PM is associated with greater mortality and a greater risk
f pulmonary hypertension or heart failure after MVR. In
ne study of 929 consecutive patients, for example, multi-
ariate analysis indicated that severe PPM was associated
ith a hazard ratio for mortality of 3.2 (95% confidence
nterval [CI] 1.5 to 6.8; p  0.003). The results highlight
he importance of implanting a sufficiently large prosthesis
n adult patients to optimize clinical results.
Patients who undergo ring annuloplasty for ischemic
itral regurgitation (MR) often have recurrent MR, al-
hough the factors that cause recurrence are unclear. It has
een suggested that late recurrent MR is caused by leaflet
ethering and remodeling of the left ventricle, which in-
reases sphericity of the left ventricle over time. Therefore,
group of Cleveland Clinic investigators examined LV
phericity and its relation to late recurrent MR after
nnuloplasty in 106 patients (48). In this echocardiographic
tudy, recurrent ischemic MR late after annuloplasty was
ssociated with decreasing left ventricular ejection fraction
LVEF) and increasing width and thus sphericity of the left
entricle during follow-up, emphasizing the ventricular
echanism of this lesion. According to Dr. Kapadia, the
V actually dilates, and the change in sphericity of the left
entricle appeared largely responsible for MR recurrence, Perhaps suggesting different ways to treat MR in this specific
ituation.
Recently in JACC, the RAAVE (Rosuvastatin Affecting
ortic Valve Endothelium) investigators reported the effects
f rosuvastatin in patients with elevated LDL and
oderate-to-severe AS (49). They evaluated the progres-
ion of AS in 121 consecutive patients with asymptomatic
oderate-to-severe AS (aortic valve area 1.0 cm2) and
ormal cholesterol levels. Patients with elevated LDL130
g/dl received rosuvastatin and those with LDL 130
g/dl did not receive the therapy. After 1.5 years of
ollow-up, treated patients demonstrated a slowing of echo-
ardiographic parameters including peak aortic valve jet
elocity, mean gradient, and aortic valve area. There was
lso a weak correlation between successful treatment of
DL and improvement of these echocardiographic param-
ters. Although this trial was not a randomized one, Dr.
apadia noted that controlling lipids in patients with
levated cholesterol levels and moderate AS appears to
ecrease disease progression.
ercutaneous Interventional Options
he use of aortic valve replacement in symptomatic patients
ith AS results in excellent symptom relief and long-term
urvival in most. However, a growing number of patients are
oor surgical candidates as the result of advanced age,
omorbidities, or previous cardiac surgery. During the past
decades, major advances have occurred in the development
f catheter-based interventions that may permit more of
hese high-risk patients to benefit from aortic valve replace-
ent, including recently published results from small trials
Table 8).
Alain Cribier, MD, FACC, developed a percutaneous
ortic valve that is usually implanted using an antegrade,
ransvenous approach for percutaneous heart valve place-
ent. From February 2004 to April 2005, 37 patients with
nd-stage AS who were formally declined for surgical valve
eplacement were included on a compassionate basis in 2
onsecutive studies (I-REVIVE [Initial Registry of Endo-
ascular Implantation of Valves in Europe]/RECAST
Registry of Endovascular Critical Aortic Stenosis Treat-
ent]), which aimed at assessing the feasibility, efficacy, and
urability of percutaneous heart valve implantation (50).
ong-term clinical and echocardiographic follow-up data
ere presented at ACC.07. Successful implantation was
chieved in 27 patients. One-month major adverse events
ere 26%, including 6 deaths attributable to noncardiac
auses. Despite being critically ill at the time of implanta-
ion, 9 patients remained alive at a follow-up 18 months
nd have returned to normal life. As shown in Figure 6,
eart valve function remained unchanged during follow-up
n the 27 patients.
Besides the Cribier-Edwards aortic heart valve (being
eveloped by Edwards Lifesciences Corporation, Irvine,
alifornia), investigators also are evaluating the CoreValve
ercutaneous Revalving System (CoreValve, Irvine, Cali-
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alve was presented at ACC.07 (51). Again, percutaneous
ortic valve replacement was performed in patients unsuit-
ble for surgical replacement. Hemodynamic and functional
mprovements were observed in all survivors, but peripro-
edural morbidity was significant and related to vascular
omplications. Of 11 patients implanted, 1 patient had a
troke and died 5 days after procedure; another patient with
mitral prosthesis had a cerebral bleed and died at 20 days.
Other studies are exploring the effectiveness of catheter-
ased approaches in repairing the mitral valve (MV). Karl
einz Kuck, MD, St. George’s Hospital, Hamburg, Ger-
any, reported the interim results of EVOLUTION (Clin-
cal EValuation Of the Edwards Lifesciences PercUTane-
us MItral AnnulOplasty System for the Treatment of
itral RegurgitatioN), which is evaluating the MONARC
ystem (Edwards Life Sciences) (52). The MONARC
ystem uses a 12-F guiding catheter and 9-F delivery system
o introduce the 2 stent-like anchors and spring-bridge
onnecting the proximal and distal anchors (Fig. 7). The
ridge contains a biodegradable element and, during the
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Figure 6 Heart Valve Function Over Time in Patients
Undergoing Percutaneous Aortic Valve Implantation
AVA  final valve area; PHV  percutaneous heart valve.
ublished Results of Percutaneous Aortic Valve Implantation
Table 8 Published Results of Percutaneous Aortic Valve Implan
No. of
Patients
Age
(yrs) EuroSCORE
Cribier Valve
Cribier (J Interv Cardiol 2006) 35 80 7 12
Webb (Circulation 2006) 18 81 6 11
CoreValve
Grube (Circulation 2006) 25 80 5 11
1 patient failed percutaneous procedure and had successful open AVR. †2 patients failed percu
AVR  aortic valve replacement; F/U  follow-up; MACE  major adverse cardiovascular eventCourse of approximately 4 to 6 weeks, the biodegradable
ubstance disappears and the spring bridge shortens, creat-
ng tension around the MV, gradually reshaping the leaflets
nd surrounding structures (Fig 8). The result is improved
eaflet function and a reduction in MR.
The study has enrolled 59 patients with moderate-to-
evere MR at baseline and dilated cardiomyopathy after
revious MI or ischemia. Interim safety data were available
t ACC.07 for 48 patients. The primary end point analysis
as event-free survival (no death, MI, or cardiac tampon-
de), which was evident in 91.4% of patients. Ninety-day
ollow-up was available for 27 patients with 13 patients
vailable for 180-day performance data analysis. Mean MR
eduction over time changed from grade 2.7 at baseline for
he overall group (baseline grade 2 to 4) to grade 1.4 at
80 days. Among the patients with the highest grade of MR
t baseline (grade 3 to 4), the mean MR was reduced from
rade 3.4 at study entry to 1.6 at 180 days. Interestingly,
lthough most patients saw at least a minimum of 1 grade
mprovement in MR during the 30 days of active device
oreshortening, improvement continued in most patients
hrough 90 days and, for some, through 180 days (Fig. 9).
his result suggests continued response and remodeling
ver time. The feasibility study did not include clinical end
oints, such as quality-of-life measures or exercise tolerance,
lthough those will be analyzed in the next large phase of
he EVOLUTION study.
The EVEREST (Endovascular Valve Edge-to-Edge Re-
air) study evaluated a percutaneous MV repair system that
onsists of a steerable guide catheter, steerable clip delivery
ystem, and the implantable MitraClip. The clip grasps and
oapts the leaflets of the MV much like surgical edge-to-
dge repair. One-year results from EVEREST I confirm
arlier findings (53) that a substantial majority of patients
ontinue to experience only mild regurgitation (54). The
VEREST Registry has data on 104 patients, with 62
eceiving 1 clip and 31 receiving 2 clips. (In the event that
dequate MR control cannot be achieved, a second clip may
e added or the first clip may be opened and removed from the
atient.) The remaining 11 patients did not receive a Mitra-
n
edural
ccess
Hospital
Post-Hospital
Mortality MACE
Aortic
Regurgitation Deaths
8% 22% 26% 50% 9
30 months’ F/U
8%* 11% NA 94% 0
3 months’ F/U
4%† 20% 32% 50% 0‡
procedure and had successful open AVR. ‡In 7 patients, follow-up 180 days.tatio
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MV  mitral valve.Although all patients had moderate (3) to severe (4)
R at baseline, acute procedural success was 85% (79 of 93
mplanted clips), defined as MR 2, of which nearly
wo-thirds had MR 1. Importantly, when the clip
rocedure cannot be successfully completed or it is per-
ormed but fails to sufficiently reduce MR or the MR
eturns, surgery remains an option. Twenty-eight patients
nderwent successful MV surgical repair up to 18 months
fter the clip procedure, and 20 (71%) were successful.
here is a procedural learning curve and, as a surgeon gains
xperience, the median time in the catheterization lab for
evice implantation decreases from 3 h or more to approx-
mately 1.5 h (Fig. 10). With up to 3-year follow-up
vailable for the 79 patients with acute procedural success,
he Kaplan-Meier curves show 97% freedom from death,
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urgery, or an MR 2. Thus, durable success is evident
or up to 36 months.
uestion and Answer
r. Thomas: It is interesting how percutaneous valve ther-
py appears to be moving from first-in-human experience to
omething—although not mainstream—it may eventually
ake a significant piece of say the aortic valve surgical
opulation.
r. Kapadia: I’m sure in the future percutaneous valve
rocedures indeed will take a significant number of surgical
atients, but it will take some time until we get to that stage.
urrently, it looks very promising.
r. Tuzcu: Mitral valve intervention, particularly with the
valve clip, has Kaplan-Meier curves extending out to 3
ears?
r. Kapadia: Yes, but at this time, 3-year data are available
or only about half of the patients receiving the clips. But,
6-month data are available and there remain stable rates of
R in patients who had good reduction in MR with the
rocedure.
r. Tuzcu: This is encouraging because, as you know, the
urgical literature had suggested that the so-called Alfieri
titch without an annuloplasty was thought to be only
pplicable for a very small minority of patients. Maybe
hat’s not the case.
r. Kapadia: Yet, even in the surgical literature, the initial
eparation of the Kaplan-Meier curves was very early on.
nly when they didn’t get a good result to start with did
hey seem to have problems later. And in surgical literature,
5% of people did well after 4 years, so this is very
omparable and very promising data.
r. Starling: These percutaneous valve techniques are
eveloping, but it was noted in another session, Controver-
ies in Valvular Heart Disease, that mortality rates for
alvular surgery are becoming extremely low, even in low
jection fraction patients. At the same time, these new
echniques offer the advantage obviously of shorter hospital
372
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Figure 10 EVEREST Trial: Procedural Learning Curve,
Single-Center Experience With MitraClip Device
Yellow bars  1-clip case; blue bars  2-clip cases.tays and not requiring mediastinotomy.
*ardiac Function and Heart Failure
eart failure is the fastest growing cardiovascular diagnosis
n the U.S., with direct and indirect costs exceeding $33
illion per year (55). There were 228 presentations related
o cardiac function and heart failure at ACC.07/i2 Summit,
ncluding several important clinical trials with negative
esults. The highlights discussion, led by Lynne E. Wag-
ner, MD, FACC, includes data from SPICE (Survival and
rognosis: Investigation of Crataegus Extract WS 1442 in
HF) (an herbal extract), FUSION II (Follow-up Serial
nfusions of Nesiritide for the Management of Patients with
eart Failure), EPHESUS (Eplerenone Post-AMI Heart
ailure Efficacy and Survival), and EVEREST (tolvaptan).
lso, data are summarized from HeartMate II, which is
valuating a new left ventricular assist device (LVAD). The
ardiac function and heart failure presentations were se-
ected from a total of 650 abstracts submitted to the
rogram Committee.
Despite the fact that a number of large clinical trials
resented at ACC.07 had largely negative results, Dr. Wag-
ner noted that there are still important lessons from these
rials evaluating newer and even some older agents. One of
he most exciting presentations, she said, included the
esults of a trial investigating an herbal agent suggesting a
enefit in class II and class III heart failure (56). The
PICE study was the first mortality/morbidity trial with an
erbal medicinal product for treating heart failure. The
gent is an extract of the hawthorn plant that has been used
or centuries in traditional European medicines to treat
eart failure. Suggested mechanisms of action include a
ositive inotrope effect, vasodilating properties, anti-
schemic effects, antiarrhythmic effects, and antioxidative
roperties As add-on treatment, WS 1442 was safe and,
ith 24 months of treatment and follow-up, the agent was
ssociated with no significant improvement in the primary
omposite end point (cardiac mortality, nonfatal MI, hos-
italization due to progressive heart failure), but with a
ignificant improvement in cardiac mortality after 6 and 18
onths as well as a significant reduction in the subgroup of
atients with an LVEF 25%, which reached significance
t 12 months; this benefit was sustained at 24 months
p  0.025).
The FUSION II trial was a 12-week study of intermit-
ent nesiritide in patients with congestive heart failure (57).
rimary Composite End Pointhrough Week 12 in the FUSION II Study
Table 9 Primary Composite End PointThrough Week 12 in the FUSION II Study
Placebo
Combined
(n  306)
Nesirited
Combined
(n  605) p Value*
All-cause mortality and
CV/renal hospitalization†
36.8% 36.7% 0.79
All-cause mortality 9.6% 9.5% 0.98
CV/renal hospitalization 33.9% 32.9% 0.95p  nesiritide versus placebo stratified by dose group; †modified ITT  all treated ITT patients.
CV  cardiovascular; ITT  intention-to-treat.
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ACC 2007 Annual Session Highlights August 21, 2007:C2–31atients were randomized to nesiritide twice or once a week
r placebo (nesiritide dosing  2 g/kg bolus, then 0.01
g/kg/min infusion for 4 to 6 h). Compared with phase I
FUSION I) (58), the FUSION II trial patients were more
han 6 times more likely to receive carvedilol and much
ore likely to receive evidence-based device therapy than
he FUSION I trial. The primary efficacy end point was
ime to all-cause death or first cardiovascular and/or renal
ospitalization through week 12.
There was no significant difference in the primary com-
osite end point, in its individual components (Table 9), or
n secondary end points, such as the number of cardiovas-
ular/renal hospitalizations, days alive out of hospital, and
ardiovascular mortality. Although nesiritide has been the
ubject of some controversy regarding its safety profile in the
etting of acute decompensated heart failure (ADHF), Dr.
agoner said, “It did demonstrate that it is a safe com-
ound. In this particular trial, there was no increased
ortality with the patients treated with nesiritide and there
as no signal of increased incidence of renal insufficiency.”
o, although the intermittent use of this agent may not be
feasible way to proceed, the encouraging safety data may
relieve some of our angst” regarding the use of nesiritide.
ore data are needed, which may come soon from the
cute Study of Clinical Effectiveness of Nesiritide in
ecompensated Heart Failure trial.
The vasopressin V2-receptor, a neural hormone, is re-
ponsible for increased fluid retention in ADHF. Fluid
etention is the primary cause of hospitalization among
DHF patients older than the age of 65, with more than 1
illion hospitalizations reported each year. Current treat-
ents for these patients have significant safety concerns and
ften are inadequate in managing fluid retention, with
ommon reports of electrolyte abnormalities and impaired
idney function. The EVEREST study evaluated a vaso-
ressin V2-receptor blocker in patients hospitalized with
DHF (59). Within 48 h of admission, patients were
andomly assigned to receive oral tolvaptan 30 mg once a
Figure 11 Kaplan-Meier Analyses of All-Cause Mortality and Ca
Mortality or Hospitalization for Heart Failure in the E
Reprinted with permission from Konstam et al. (61).ay (n  2,072) or placebo (n  2,061) for a minimum of
0 days, in addition to standard therapy. Rank sum analysis
f the composite primary end point for short-term clinical
ffects showed greater improvement with tolvaptan versus
lacebo (p  0.001). Patients who received tolvaptan lost
ore body weight, had more fluid loss, and had greater
evels of serum sodium (60). However, there was no signif-
cant difference between the groups in global clinical status.
During a median follow-up of 9.9 months, 537 patients
25.9%) in the tolvaptan group and 543 (26.3%) in the
lacebo group died (p  0.68) (61). There was no signifi-
ant difference in the composite of cardiovascular death or
ospitalization for heart failure, which occurred in 871
atients receiving tolvaptan (42.0%) and 829 patients re-
eiving placebo (40.2%; p  0.55), nor was there any
ifference in the individual outcomes of the composite end
oint (Fig. 11). Thus, despite short-term benefits, tolvaptan
nitiated for acute treatment of patients hospitalized with
DHF had no effect on long-term mortality or heart
ailure-related morbidity.
According to Dr. Wagoner, this was an interesting trial
ecause vasopressin antagonists typically have been studied
n the use of hyponatremia and volume overload, including
uvolemic as well as hypovolemic hyponatremia. She said,
This is the first trial of this type of compound used for
eneral heart failure.” Also, she noted, patients were admit-
ed for ADHF, yet there was a very low incidence of
yponatremia (7% to 8% in each arm) suggesting, perhaps,
hat this was not a “really, really sick or chronically sick
opulation,” which may have had something to do with the
egative long-term results. Nevertheless, Dr. Wagoner said,
olvaptan was associated with a loss of fluid weight without
n increase in renal insufficiency. “We need to know more,”
he said, “but hopefully this is a drug class we’ll be using
own the road for treating heart failure.”
New data for an older drug were presented in the
PHESUS study, originally published by Pitt et al. in
003 (62). This subanalysis of the original trial data
ascular
ST Trialrdiov
VERE
c
a
h
b
2
l
m
a
T
r
l
a
i
r
o
c
t
p
t
o
a
p
a
t
c
c
a
m
s
(
s
o
i
p
s
t
s
m
a
t
r
c
f
b
p
p
n
a
o
5
a
c
b
c
p
e
a
D
e
c
t
d
i
f
h
w
w
p
(
d
p
d
m
HA
*
C19JACC Vol. 50, No. 8 Suppl C Tuzcu et al.
August 21, 2007:C2–31 ACC 2007 Annual Session Highlightsompared early (3 to 7 days) versus late (8 to 14 days)
dministration of eplerenone versus placebo (63). The
ypothesis was that early administration of an aldosterone
locker would improve outcomes, based at least in part on
006 data demonstrating the pivotal role of aldosterone
evels on survival after STEMI (64). Aldosterone, the final
ediator of the renin-angiotensin-aldosterone pathway, is
t its highest plasma levels at presentation after STEMI.
he study by Beygui et al. (64) showed that, among patients
eferred for primary PCI for STEMI, plasma aldosterone
evels on admission were associated with early and late
dverse clinical outcomes, including mortality, and the
ncreased risk was independent of age, heart failure, and
eperfusion status.
The new EPHESUS subanalysis used the original cohort
f post-acute myocardial infarction (AMI) patients with
linical heart failure and LVEF 40%. Randomization was
o eplerenone (25 mg titrated to 50 mg/day; n  3,313) or
lacebo (n  3,319) in addition to standard heart failure
herapy 3 to 14 days after AMI. Within each group,
ne-half of the patients had early initiation of drug therapy
nd one-half had late initiation. Among the primary end
oints (Table 10) at 16 months, there was a 23% decrease in
ll-cause mortality in favor of early eplerenone administra-
ion (p  0.003 vs. placebo). The coprimary end point of
ardiovascular death or hospitalization for cardiovascular
auses also showed greater benefit associated with early
dministration of eplerenone (p  0.01 vs. placebo). The
ost striking difference was the 37% decreased risk of
udden death associated with early initiation of eplerenone
95% CI 0.48 to 0.84; p 0.002). Conversely, patients who
tarted taking eplerenone after the first week enjoyed none
f these benefits. Said Dr. Wagoner, “Going forward, this is
nformation we need to carry back to our practice and it will
otentially impact our guidelines for the initiation of aldo-
terone blockade post-MI.”
Does eplerenone affect remodeling? Dr. Wagoner noted
he results of another paper presented at ACC.07 demon-
trating that patients with LV dysfunction and mild-to-
oderate heart failure treated with eplerenone had no
dditional effect on LV remodeling over and above standard
herapies (65). “Whatever benefits occur with this aldoste-
one blocker are not due to LV remodeling,” she said.
Mechanical circulatory support with an LVAD has be-
ome a standard therapy for patients with refractory heart
Clinical Outcomes at a Mean of 16 Months AssW th Early Initiation (3 to 7 Days) of Eplerenone
Table 10 Clinical Outcomes at a Mean of 1With Early Initiation (3 to 7 Days)
Placebo
(n  1,804)
All-cause mortality 293 (16.3%)
CV mortality or CV hospitalization 529 (29.3%)
Sudden cardiac death 122 (6.8%)
CV death 253 (14.0%)
CI  confidence interval; CV  cardiovascular.ailure as a bridge to heart transplantation. New devices are eeing examined for their safety and efficacy in the growing
opulation of patients awaiting transplantation as well as in
atients deemed ineligible for heart transplantation. One
ovel LVAD called HeartMate II (Thoratec Corp., Pleas-
nton, California) uses miniature continuous flow technol-
gy designed to provide mechanical circulatory support for
to 10 years. The implantable LV assist system, powered by
rotary pumping mechanism, is significantly smaller than
urrently approved devices, enabling easier implantation in a
roader population of patients, and it is much quieter than
urrently available units because it has only a single moving
art. In a prospective, multicenter trial, 133 patients were
nrolled at 26 centers from March 2005 through May 2006,
nd the data reported reflect patient follow-up through
ecember 2006 (66). In this trial, the device was being
valuated as a bridge to transplantation; a separate ongoing
linical trial is evaluating the HeartMate II as destination
herapy.
In this nonrandomized, phase II, prospective study,
evice placement led to rapid improvements in both cardiac
ndex and pulmonary capillary wedge pressure (p  0.001
or both vs. baseline) within 24 h of implantation. One
undred patients (75%) met the trial’s primary end point,
hich was cardiac transplantation or survival at 180 days
hile remaining eligible for transplantation. There were 68
atients (51%) who underwent transplantation with 29
21.8%) continuing on LVAD support for longer than 180
ays (average duration of support: 168  148 days). Three
atients showed unexpected cardiac recovery permitting
evice explantation. A total of 33 patients (24.8%) did not
eet the primary end point, mostly as the result of death on
ede EPHESUS Study
nths Associated
lerenone in the EPHESUS Study
Eplerenone
(n  1,793)
Hazard Ratio
(95% CI) p Value
229 (12.8%) 0.77 (0.65–0.92) 0.003
457 (25.5%) 0.85 (0.75–0.96) 0.01
78 (4.4%) 0.63 (0.48–0.84) 0.002
200 (11.2%) 0.78 (0.65–0.94) 0.009
eartMate (HM) II Clinical Trial:dverse Event Rates HM II Versus HM VE
Table 11 HeartMate (HM) II Clinical Trial:Adverse Event Rates HM II Versus HM VE
Adverse Event
Events per Patient-Year
Continuous Flow
HM II
(62 patient yrs)
(n  133)
Pulsatile Flow
HM VE*
(86 patient yrs)
(n  280)
Bleeding requiring surgery 0.78 1.47
Percutaneous lead infection 0.37 3.49
Stroke 0.19 0.44
Nonstroke neurological 0.26 0.67
RV failure requiring RVAD 0.08 0.30
Frazier OH, et al. J Thorac Cardiovasc Surg 2001;122:1186–95.ociatin th
6 Mo
of EpHM  HeartMate; RV  right ventricular; RVAD  right ventricular assist device; VE  vented
lectric.
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ACC 2007 Annual Session Highlights August 21, 2007:C2–31he device within 180 days. The data also showed that the
rial met or exceeded the objectives for the secondary end
oints, including frequency of adverse events, improved
unctional status, and enhanced quality of life.
According to Dr. Wagoner, “It was a very positive trial
nd the key point here to take home was the fact that this
eartMate II continuous flow device was associated with
ess bleeding, fewer infections, less stroke, and less need for
right ventricular assist device after implantation compared
ith [the pulsatile flow HeartMate VE]” (Table 11). “The
essage here is we’re getting better with our left ventricular
ssist device therapy and the HeartMate II device is likely to
o forward and replace our current HeartMate VE,” she
dded.
uestion and Answer
r. Starling: That’s exciting. There may be some light at
he end of the tunnel for our hope of chronic therapy with
hese devices with the new axial flow designs.
r. DeMaria: If you were to project in the future 5 to 10
ears, given smaller more effective devices, what role do you
ee for transplantation? Do you see it diminishing dramat-
cally as these small devices come on line?
r. Wagoner: Obviously there is a huge cohort of patients
ho will never have the benefit of cardiac transplantation.
ventually, we will have a large cohort of patients going on
evice therapy. There is still a ways to go in terms of
howing long-term benefit with these devices, but certainly
he profile of these looks much more promising than the
urrent systems we have, which tend to have a life expect-
ncy of only about a year to a year and a half.
r. Starling: Tony, just to give you quickly my editorial
omments on that question. Transplantation survival is 85%
o 95% at 1 year, but that’s at the cost of long-term
mmunosuppression, which isn’t pretty, and perhaps 10% of
atients having end-stage renal disease by 5 years. Given
hese results, we’re going to see devices like (HeartMate II)
ove from class IV patients to appropriate therapy for kind
f a refractory class III patient population. This is clearly
oing to be the wave of the future.
r. Conti: Lynne, let’s go back to another study for a
oment. FUSION II enrolled sick heart failure patients
ho had 2 prior hospitalizations. When we look at the days
live and out of the hospital and the number of hospital-
zations, we don’t see any differences. One of the messages,
s I see it, is that for patients who come into the clinic once
r twice a week—and in some cases receive intravenous
iuretics—we can really have an impact.
r. Wagoner: Absolutely. Patients in both arms of FU-
ION II received good careful attention from a multidisci-
linary heart failure team. Perhaps that’s the most important
esson from this particular trial.
Going forward, it appears that the intermittent use of an
gent, either nesiritide or inotrope, is probably not a
easonable way to go. For those patients in the community
aving trouble with repeat hospitalizations, perhaps the way eo go is to consider referral of these patients to a multi-
isciplinary heart failure program.
r. Starling: It’s also important to point out that the use of
notropes was really not allowed in this trial, which perhaps
ontributed to the greater event rate in the study than
USION I. And as we heard in the preliminary results of
OURAGE (67), evidence-based medicine is very impor-
ant and all of these patients in FUSION II had their
ngiotensin-converting enzyme inhibitors and beta-blockers
ptimized.
r. Wagoner: And these trials are being conducted in the
ra of increased ICD use. That will likely have an effect on
ortality outcome with a lot of these trials.
r. Conti: Lynne, tell me again the timing of the use of the
ldosterone blocker in EPHESUS.
r. Wagoner: This substudy of the original EPHESUS trial
sed 7 days as the cutoff for early versus late initiation. Early
nitiation was a mean of 5.5 days.
r. Conti: That message needs to be explained carefully
ecause you don’t want to be giving this drug to unstable
atients with AMI and heart failure because of the com-
lexities of giving all the other drugs they require, including
ome that raise potassium.
r. Wagoner: The message is to try to get eplerenone
nboard before 7 days; it definitely is not a drug you’re going
o be giving in the emergency department as they come in
he door.
r. Tuzcu: Is this going to be a medication that we are
oing to be score-carded on? We now are measured by how
any patients we have on angiotensin-converting enzyme
nhibitors, statins, aspirin, and so forth. Is this going to be
drug for all myocardial infarction patients or. . . .
r. Conti: If ejection fraction is 40%, it’s a class I
ndication now. Isn’t that right, Lynne?
r. Wagoner: That is right. Yes, it potentially could be one
f the drugs used for quality assessment in that population.
ardiac Arrhythmias
t the 2007 ACC Scientific Session and i2 Summit, there
ere 153 accepted abstracts in the topic area of cardiac
rrhythmias, including a comprehensive meta-analysis of
utcomes and safety data for ICDs and cardiac resynchro-
ization therapy (CRT). The highlights discussion, led by
r. Markowitz, also included results from the ALPHA
T-Wave Alternans in Patients With Heart Failure) trial
nd a summary of new technologies and techniques for
blation of atrial fibrillation. The cardiac arrhythmia pre-
entations were selected from a total of 424 abstracts
ubmitted to the Program Committee.
According to Dr. Markowitz, the most exciting sessions
ere the live and recorded cases from various centers around
he world, including a live case using ablation therapy to
reat ventricular arrhythmia and a live lead extraction done
y Charles L. Byrd, MD, FACC, during the session
ntitled Challenges in Device Implantation and Extraction
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August 21, 2007:C2–31 ACC 2007 Annual Session Highlights68). “In fact,” said Dr. Markowitz, “after that extraction,
r. Byrd extracted a vegetation from the heart that was
dherent to the wall that was next to the leads. It was a very
xciting case and the first time any of us had seen this,
ncluding all the experienced panelists.”
With regard to data presented at ACC.07/i2 Summit, he
aid there were important studies on risk stratification for
udden death, which is common in patients with heart
ailure despite the use of optimal therapy. Ezekowitz et al.
69) conducted a systematic review to determine the com-
arative efficacy, effectiveness, and safety of CRT and ICDs
n patients with heart failure. (The CRT analysis was
ubsequently published in June 2007) [70]. Dr. Markowitz
oted that the comprehensive meta-analysis was sponsored
y the ACC, American Heart Association, and Heart
hythm Society, and it included all known ICD trials to
ate, published and unpublished, including randomized and
bservational trials. The studies included primary and sec-
ndary indications for ICD or CRT in the management of
entricular arrhythmias in nonischemic cardiomyopathy pa-
ients, ischemic populations, as well as early post-MI and
ate post-MI patients. “A very heterogeneous group of
tudies and very comprehensive,” said Dr. Markowitz.
The analysis suggests that ICDs indeed reduce the risk of
eath, with a relative risk of death of 0.80. Importantly, the
umber needed to treat to save 1 life after 35 months was 20
atients. “That number is somewhat larger than some of the
andmark trials,” said Dr. Markowitz, “because it included
rials with less of an impact, less of a treatment effect.” As
or CRT, the systematic review suggests a relative risk of
eath of 0.78 and number needed to treat of 13 patients to
ave 1 life after 2 years. He said the data underscore the
trong need to identify reliable risk stratifiers among heart
ailure patients who are candidates for ICD prophylaxis.
lso, he added, “We need to be cognizant in the cardiology
ommunity of not only the economic impact but the
edical risk of implanting these devices and the psycholog-
cal burden.”
-Wave Alternans (TWA)
he need to better stratify patients for sudden death risk is
articularly true for patients with heart failure of nonisch-
mic origin. In general, there are several significant predic-
ors of arrhythmic events that can be assessed noninvasively,
uch as impaired heart rate variability 20 ms, late poten-
ials, ventricular ectopic beat frequency, repetitive ventricu-
ar forms, LVEF 40%, and Killip class. However, speci-
city is low as is the positive predictive value of each of these
arkers. Moreover, there are limited data on the value of these
arkers in patients with nonischemic cardiomyopathy.
T-wave alternans have a greaer specificity in predicting
rrhythmic events and may identify low-risk subjects among
post-MI population with depressed LV function, but their
redictive role in nonischemic heart failure also is unclear.
he ALPHA study enrolled 446 stage II and III heart Tailure patients with nonischemic cardiomyopathy, LVEF
40%, and no history of malignant arrhythmias (71). In
his primary prevention study, patients were given a TWA
est at 9 hospitals in Italy and followed for 18 to 24 months
o assess combined rates of cardiac death plus life-
hreatening ventricular arrhythmias (the primary end point),
ll-cause mortality rates, the combination of arrhythmic
eath plus life-threatening arrhythmias, and hospitalization
ates. In the patients studied, there were 154 negative TWA
ests, 200 positive tests, and 92 indeterminate tests; the
atter 2 groups were combined for a total of 292 patients
ith abnormal TWA tests.
Salerno-Uriarte et al. (71) reported that an abnormal
WA test was associated with a much greater risk of cardiac
eath and arrhythmic death compared with patients with a
ormal TWA (Table 12). Also, during follow-up, there was
much greater incidence of arrhythmias and hospitaliza-
ions in the abnormal TWA group. The Kaplan-Meier
urves for the primary end point separated early on, and the
ifference at 21 months was significant (p  0.002) (Fig.
2). The unadjusted hazard ratio for an abnormal TWA test
as 4.01; after adjusting for age, gender, New York Heart
ssociation (NYHA) functional class, and LVEF, the
azard ratio was 3.21 (hazard ratio 1.12 to 9.22; p 0.013).
he authors concluded that among patients with NYHA
unctional class II or III nonischemic cardiomyopathy, an
bnormal TWA is associated with a 4-fold greater risk of
ardiac death and life-threatening arrhythmias. Conversely,
atients with a normal TWA test have a very good prog-
osis and are unlikely to benefit from ICD therapy. Dr.
arkowitz said the ALPHA trial results are “pointing the
ay to the future,” although other trials are expected to
ore fully explore the use of TWA testing.
As for resynchronization, 1 study looked at predicting
esponse to biventricular pacing. Dyssynchrony plays a role
n CRT response, but dyssynchrony patterns may be com-
lex and the optimal quantitative approach is unclear. Most
tudies to date have involved detecting longitudinal dyssyn-
hrony with tissue wave Doppler. Gorcsan et al. (72) studied
73 NYHA functional class III to IV heart failure patients
ndergoing CRT, and dyssynchrony was assessed in 2
lanes: longitudinal with tissue Doppler measures of veloc-
ty and radial using speckle tracking radial strain (i.e.,
vents During Follow-Up in the ALPHA Study
Table 12 Events During Follow-Up in the ALPHA Study
Event
All
Patients
(n  446)
Abnormal
TWA
(n  292)
Normal
TWA
(n  154)
Total mortality 28 25 3
Cardiac death 18 16 2
Arrhythmic death 7 7 0
Symptomatic sustained VT or VF 11 9 2
Documented VF 4 4 0
Sustained VT revealed by device 4 4 0
Hospitalization 85 61 24WA  T-wave alternans; VF  ventricular fibrillation; VT  ventricular tachycardia.
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ACC 2007 Annual Session Highlights August 21, 2007:C2–31hickening of the wall in the radial dimension). If dyssyn-
hrony with both measures was present, the response rate to
RT was very high (Fig. 13). If neither was present, then
he response rate was much lower. Said Dr. Markowitz,
The results suggest we have some way to go to improve
pon our ways to assess dyssynchrony by echocardiography.”
In a separate study in the same session, investigators found
hat MR at baseline also predicted poor response to CRT (73).
n a retrospective analysis of the DECREASE-HF (Device
valuation of CONTAKRENEWAL 2 and EASYTRAK 2:
ssessment of Safety and Effectiveness in Heart Failure)
atabase, patients with greater MR at baseline (grade 3 or 4),
s well as patents who developed MR after device implanta-
ion, fared less well in terms of improvement in peak VO2 and
entricular remodeling.
trial Fibrillation (AF)
ate control is a reasonable management strategy for many
atients with AF. However, the majority of patients en-
olled in the clinical trials evaluating rate control still had
ersistent AF.
Two epidemiologic studies presented at ACC.07 ad-
ressed the question of rate versus rhythm control. One
tudy analyzed data from a retrospective cohort of a large
ealth benefits company (74). Individuals with new-onset
F were stratified into 2 categories using pharmacy utiliza-
ion codes: rate control only and rhythm (antiarrhytmics)
ontrol. Of a total 19,341 patients, 14,093 subjects (72.9%)
ere in the rate-control group and 5,248 subjects (27.1%)
ere in the rhythm-control group. During 12-month
ollow-up, 7,160 patients were hospitalized and 2,347 had a
troke. Cox proportional hazard models were used to
stimate the relative hazard of stroke and hospitalization.
he relative hazard of hospitalization for individuals in the
Months0·00
0·25
0·50
0·75
1·00
0 3 6 9 12 15 18 21
Normal TWA Abnormal TWA 
p=0·002
154
292
152
275
117
201
154
281 Study
Figure 12 Event-Free Survival in the ALPHA
Study Based on the Primary End Point
Primary end point is cardiac death and life-threatening arrhythmias.
TWA  T-wave alternans.hythm-control group was 1.12 (95% CI 1.07 to 1.18)ompared with those in the rate-control group after adjust-
ng for demographics, congestive heart failure, MI, hyper-
ension, diabetes, abnormal lipids, and peripheral vascular
isease. The relative hazard of stroke for patients in the
hythm-control group was 1.16 (95% CI 1.05 to 1.29)
ersus those in the rate-control group adjusted for the same
ovariates plus the use of warfarin. Also, adjusted 1-year
otal health care costs were greater for the rhythm-control
roup ($37,828; 95% CI $36,575 to $39,080) when com-
ared with the rate-control group ($31,902; 95% CI
31,141 to $32,664). Said Dr. Markowitz, “Marginally
igher health care utilization costs and stroke incidence, so
o benefit to rhythm control in this population.”
Similar results were evident in a different analysis of AF
nd diastolic heart failure (75). Although no clinical trial
vidence exists on the optimal management of AF in
atients with isolated diastolic heart failure, it has been
ypothesized that rhythm control is more advantageous due
o the dependence of these patients’ LV filling on atrial
ontraction. Investigators used the Duke Cardiovascular
atabase (1995 to 2005) to identify patients with diastolic
eart failure and then sought to determine whether such
atients survive longer with rhythm versus rate control.
A total of 471 patients met inclusion criteria; 338 (71.8%)
ere treated with rate control and 133 (28.2%) treated with
hythm control. There was little difference in 1-, 3- and
-year survival rates between the 2 groups (p  0.1). After
aseline adjustments, no difference in mortality was evident
Fig. 14). “The implications here are that in patients who
re minimally symptomatic, whose rate can be adequately
ontrolled—especially in the older segment of the popula-
ion—rate control is a perfectly acceptable strategy if not
referable and that physicians can feel comfortable and not
ompelled to restore sinus rhythm in that majority of patients
xperiencing atrial fibrillation,” said Dr. Markowitz.
Figure 13 Predictive Value of Dyssynchrony Patterns
Dyssynchrony was assessed in 2 planes: longitudinal (tissue Doppler imaging)
and radial (speckle tracking radial strain). Response was defined as end-sys-
tolic volume (ESV) decrease 10% or ejection fraction (EF) increase 15%. Of
173 patients, 119 (69%) were EF responders. Light blue bars  ESV respond-
ers; dark blue bars  EF responders. *p  0.05 versus both; #p  0.05 ver-
sus either.
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August 21, 2007:C2–31 ACC 2007 Annual Session Highlightsuestion and Answer
r. Thomas: That really could be a paradigm shift if this
ecomes commonly held—and is really borne out in the
uture with additional studies.
r. DeMaria: It still doesn’t account for quality of life, does
t? And my recollection of the data is that quality of life still
eems to be a little bit higher if you’re in normal sinus
hythm.
r. Markowitz: If you can maintain sinus rhythm. That’s
hy I qualified my comments and slipped in that patients
ave to be minimally symptomatic with adequate rate
ontrol. I would also caution that most of these studies, such
s the randomized AFFIRM (Atrial Fibrillation Follow-up
nvestigation of Rhythm Management) study (76), involved
lder patients and this does not necessarily apply to the
0-year-old patient with paroxysmal AF. They are often
ery symptomatic and in those patients rhythm control is
uch more important. Also, rhythm control may be much
ore important in patients with heart failure exacerbations.
r. Starling: Any cool new technology that you can use
hen you actually need to do these techniques?
r. Markowitz: Funny you mention that because, yes, we
id hear about some novel technology. There are instances
here we have to maintain sinus rhythm, and antiarrhyth-
ic drugs have been disappointing and associated with
ubstantial toxicities. Atrial fibrillation ablation has been
oving more and more into the mainstream over the years,
nd there has been an effort to develop new technologies to
mprove the efficacy of AF ablation. One such technology
resented at the meeting, a catheter that is a combined
ltrasound mapping catheter, is in preclinical studies. It’s
National Institutes of Health-sponsored bioengineering
esearch project. And the other topics discussed with
egard to AF ablation were differential approaches to
reating persistent versus paroxysmal AF in the labora-
Figure 14 Survival Curves for Rate Versus Rhythm Control
in Patients With AF and Diastolic Heart Failure
Using a 60-day landmark view to assess medication usage, Kaplan-Meier
curves for rate versus rhythm control were adjusted for baseline patient differ-
ences using Cox proportional hazards modeling. AF  atrial fibrillation.ory. New types of energy delivery may hold promise for the future. Also, studies are underway on how to inte-
rate imaging into the lab whether it’s CT, magnetic
esonance, or echocardiography, as well as the emerging
ole of robotic technology.
r. Tuzcu: I want to go back to this idea of stratifying
atients for risk of sudden death; it is interesting as we try
o get some control over costs. If we really go ahead and put
efibrillators and CRT devices in all these patients based on
V function criteria, it is going to be very difficult to afford
ll these devices, not only in the U.S. but everywhere else.
ou’re suggesting that in the near future we will probably
ave some predictive models that will help us to select the
est patients for these techniques?
r. Markowitz: In terms of CRT, yes, I believe we will. The
hallenges are 2-fold in terms of assessing dyssynchrony as a
uide for CRT implantation. First, we have to be able to make
his efficient and practical in clinical practice. Right now in the
etting of an academic institution or as part of a research study,
e can assess dyssynchrony offline with complex programs. It
ay indeed hold prognostic significance, but how are we going
o translate that into the clinical arena so a physician can do it
n his office and select the patient for CRT? The second
hallenge is to show these measures can predict not only
emodeling—most of the end points have been anatomical
emodeling—but we want to show that we can use these
election criteria to choose patients and then achieve hard
utcomes that reduce heart failure, hospitalizations, and
mprove mortality.
r. Thomas: There are very important data on speckle
racking because it’s emerging as a very robust way of
ooking at cardiac mechanics. Although still largely confined
o academic laboratories, it actually is pretty easy to do. It’s
asier probably than tissue Doppler-based indices and as
ackages get migrated from offline analysis onto the ma-
hine, you’ll see sort of some push-button approaches to this
hat should be much more convenient and applicable in the
eneral population.
r. DeMaria: I’ll throw some controversy in here. This is
et another criterion of unproven value in determining
hether or not somebody should get biventricular pacing.
t’s maybe the fifth or sixth such criteria, but none of them
re really perfect and to deny a patient in heart failure the
enefit of CRT and risk missing some of the 24% who
ight respond is intellectually attractive but functionally not
oo helpful.
r. Markowitz: That’s a good point. Right now we’re left
ith making decisions based on depressed LV function,
ncreased LV dimensions, and a wide QRS.
r. Thomas: But this could be applicable to patients who
therwise wouldn’t fit the criteria but have evidence of
yssynchrony or a narrow QRS complex. Those studies are
nes we’re still waiting to hear from.
r. Markowitz: Also, we want to do no harm as well. Of
ourse, we don’t want to miss responders, but if someone
oesn’t have dyssynchrony, especially if we’re talking about
he populations you were referring to in the future, poten-
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acing both ventricles. It’s not clear that pacing both
entricles is better than normal native conduction. Probably
t is not.
r. Starling: Steve, at this point in time the guidelines tell
s to select patients with nonischemic cardiomyopathy, EF
0% or less, NYHA functional class II and III, and if they
eet the criteria, consider an ICD.What do we do with this
-wave alternans information?
r. Markowitz: I would advocate that everyone practice
ccording to those guidelines, but it’s possible that the
uidelines will be modified in the future in light of further
ata.
Several more TWA studies are expected in the future.
e have one multicenter study presented last year, called
he ABCD (Alternans Before Cardioverter Defibrillator)
tudy (77), which did suggest that TWA had good negative
rognostic value. In that population, combined with inva-
ive electrophysiology studies, those patients have the lowest
vent rate. But we’re expecting further studies in the
schemic population and the nonischemic population. If
hose bear out the predictive value of TWA, it’s very
ossible that we could modify the recommendations.
r. Conti: One comment I have regarding any laboratory
est is that they all look good in populations, but you still
ave the problem: What do you do with the individual
here you’re not quite sure it’s positive or negative? You still
ave to use the compilation of all the things that we look at
ather than focusing on one thing. I like TWA and it’s got
otential, but you still have to look at the big picture.
I don’t know how many in the audience know about
peckle tracking. The only thing I know about it is what Jim
homas taught me about it 4 or 5 years ago and I’m not sure
verybody knows what it is or, if they do, they have it on
heir machines.
r. Thomas: It’s not on all machines, but it’s spreading
retty rapidly. All manufacturers are working on it. It’s
asically looking at deformation of the ventricle using the
ctual little speckles that you see. We used to call that
noise” and try to ignore; now we’re trying to analyze them.
maging and Diagnostic Testing
total of 329 abstracts related to imaging and diagnostic
esting were accepted for presentation at the ACC.07
cientific Session, selected from a total of 904 abstracts in
his category submitted to the Program Committee.
r. Villanueva offered a number of general impressions and
hemes from the annual meeting and i2 Summit.
She picked up on a theme Dr. DeMaria raised during the
ighlights discussion on cardiac arrhythmias: the prolifera-
ion of yet more new criteria based on advances in technol-
gy and imaging. Reviewing all of the abstracts in imaging,
r. Villanueva agreed that diagnostic imaging technology
eeps advancing, “arguably at a faster rate than we can digest
hem,” with imaging options that are increasingly diversend complex. There are ongoing debates, too, further
omplicating matters: the benefits of better visualizing
natomy (computed tomography angiography [CTA]) ver-
us physiology (myocardial perfusion imaging [MPI]); the
uestion of when a deeper level of visualization is necessary
o study endocardial necrosis (cardiac magnetic resonance
CMR]), plaque components (CMR, positron emission
omography [PET]/CT), or do molecular imaging (CMR,
ET, echocardiography); and there is ongoing concern
egarding the incremental value of any given imaging
trategy versus convenience versus safety versus costs. Con-
equently, Dr. Villanueva said, “The challenge for the
linician is how to balance the appeal of pretty pictures, of
hich we’ve seen so many at this conference, with the
ational use of technology on behalf of the patient.”
In a session on Integrated Imaging in Diagnosis and
anagement of Coronary Artery Disease, Robert M. Califf,
D, MACC, asked: what is the evidence base in imaging?
78) On the basis of ACC/American Heart Association
uidelines relating to imaging, there are 745 recommenda-
ions, half of which are class I; however, in terms of
strength of evidence,” only 1% of those class I recommen-
ations are level A (Fig. 15). (Level A evidence is based on
ata derived from multiple randomized clinical trials or
eta-analyses.) “This is a problem we have to fix,” said
r. Califf in his presentation. “I am pleased to say that
ichael Wolk, Steve Nissen, and the other leaders of the
CC have been taking this very seriously and continue
eveloping appropriateness criteria for cardiovascular imag-
ng.” In that spirit, Dr. Villanueva used her highlights
ummary to cite a few studies where imaging made—or may
ake—a difference, i.e., where evidence-based imaging can
e used to enhance patient care.
ARR-2 (The PET and Recovery
ollowing Revascularization) Study
ositron emission tomography is a widely used research tool
o map normal heart function and may be beneficial in
elping physicians select therapies by visualizing a patient’s
eart metabolism. For example, patients with heart failure
ight benefit from revascularization, but they also are at
igh risk for perioperative events. Viability imaging meth-
13%
18%
18%
I: 51%
Class I
Class IIa
Class IIb
Class III
Level B 
45%Level C 
54%
Level A
1%
Level A
Level B
Level C
745
Recommendations
“Strength” of 
the evidence 
Figure 15 Evidence Base in Imaging: Guidelines
Recommendations Versus “Strength” of Evidence
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August 21, 2007:C2–31 ACC 2007 Annual Session Highlightsds might be able to predict which heart failure patients are
ost likely to benefit from revascularization.
The PARR-2 study is the largest randomized study to
valuate whether fluorodeoxyglucose (FDG)-PET-
irected therapy has a beneficial effect on clinical out-
omes (79). Investigators enrolled 430 patients with poor
V function (LVEF 35%) and used PET imaging to
uide therapy choices in an effort to improve clinical
utcome compared with standard therapy. The investi-
ators noted that it is the first randomized trial to
valuate viability imaging with a focus on patients with
evere LV dysfunction.
Study patients were being considered (but not accepted)
or revascularization, cardiac transplantation, heart failure
orkup, or were—in the opinion of the attending physician
r surgeon—likely to benefit from FDG-PET-guided ther-
py. A total of 218 patients received PET-guided therapy
nd 212 patients received standard therapy. Researchers
racked the composite rates of cardiac death, heart attack,
ransplantation, or rehospitalization for cardiac reasons. The
tudy found that patients with poor LV function who
eceived FDG-PET-guided therapy had fewer cardiac
vents over the course of 1 year compared with patients who
eceived standard care (hazard ratio  0.81), but this rate
id not reach statistical significance. However, among those
atients who had not recently undergone angiography,
ET-guided therapy significantly reduced cardiac death
ates compared with those receiving standard care (hazard
atio 0.4; p 0.035) (Fig. 16). Overall, the study was too
mall to detect a significant benefit with PET imaging.
owever, compared with standard care, the FDG-PET arm
id have more patients directed to revascularization and
ended to reduce cardiovascular events within 1 year, al-
hough this did not reach statistical significance. The
nvestigators then took a closer look and found that patients
ithout recent angiography tended to be an older and sicker
0030020010
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
Standard arm
PET arm
Days 
Figure 16 Survival Free of Cardiac Death
in Patients Without Recent Angiography
Chi-square  4.5; hazard ratio  0.4; 95% confidence interval  0.17 to 0.96;
p  0.035. PET  positron emission tomography.roup and there was a significant decrease in cardiac deathf they received PET-guided therapy. While acknowledging
he study was inconclusive with respect to the primary
utcome measurements, the authors concluded, “The results
ppear promising in supporting the use of FDG-PET
iability imaging in this patient population.”
rognostic Information
r. Villanueva also cited a few studies in which imaging
ppears to offer prognostic information. A multicenter study
valuated 1,602 consecutive patients with known or sus-
ected CAD who were referred for rest/stress PET-CT
80). The CT was used only for attenuation correction. A
7-segment model and a 0 to 4 scale were used and summed
tress score was computed. During follow-up (median 511
ays), 113 patients (7%) died. The results offer the first
vidence of the incremental prognostic value of myocardial
erfusion PET-CT imaging when used in addition to
linical variables in patients with known or suspected CAD
Fig. 17).
Another study concentrated on patients with abnormal
PI but no significant CAD by angiography. Morse et al.
81) hypothesized that these “false-positive” MPI patients
ould have a greater risk of mortality compared with
ubjects with normal MPI. Indeed, patients with abnormal
PI but normal catheterization had significantly decreased
urvival over an average 5.2 years of follow-up compared
ith individuals with normal MPI. “These traditionally
alse-positive patients may actually have worse outcome,”
aid Dr. Villanueva. Plus, she noted, these patients had
ore clinical predictors of endothelial dysfunction, notably
iabetes, hypertension, and obesity, than those with a
ormal MPI. Therefore, despite the reassurance of no
bstructive CAD, the data suggest that these “false-
ositive” MPI patients may have endothelial dysfunction
hat would not be detected by standard angiography. This
Figure 17 Increases in PET SSS Translates Into
Proportional Increases in Predicted Mortality
p  0.0003. PET  positron emission tomography;
SSS  summed stress score.
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isk factors.
Cardiac CTA, with its excellent negative predictive value,
s a good tool for evaluating symptomatic patients with an
ntermediate likelihood of CAD. Investigators sought to
valuate the prevalence of normal and nonobstructive CAD
50% stenosis) in an outpatient setting using CTA and
hen analyze the clinical outcomes in those patients over a
eriod of 30 months (82). The investigators reported an
xcellent 30-month prognosis in this population of symp-
omatic patients with suspected CAD, thereby confirming
he strong negative predictive value of this technology.
Dr. Villanueva finished up with 3 studies that used
maging that might guide clinical decisions in therapy. One
sed 64-slice multidetector CT as a first diagnostic ap-
roach in patients presenting to the emergency department
ith acute chest pain (83). Randomization was to a con-
entional diagnostic strategy versus CTA to make a decision
bout admission. In a high-risk group (definite angina but
ncertainty regarding myocardial infarction), there was no
ifference between multidetector CT versus a conventional
trategy. However, in intermediate- and low-risk groups
probable angina and probable not angina), unnecessary
dmission was significantly reduced with multidetector CT
p  0.037).
Improvements in LV function and reverse remodeling
fter CRT are larger in patients with nonischemic dilated
ardiomyopathy than in patients with ischemic dilated
ardiomyopathy. In the second study cited, investigators
sed CMR imaging to evaluate the influence of scar burden
n response to CRT (84). Dr. Villanueva said, “[CMR]
redicted response to CRT with a threshold of scar burden
redicting no response at all to CRT.”
Finally, transplantation of circulating progenitor cells has
een shown to improve LV function after successful recan-
lization of a chronic total occlusion at short-term follow-
p. Thiele et al. (85) used CMR imaging to serially assess
hanges in LV function in an effort to uncover underlying
echanisms by measuring myocardial perfusion and infarct
ize at mid-term (3 months) and long-term (15 months)
ollow-up. In analyzing total scar burden, they found that
MR predicted response to intracoronary circulating pro-
enitor cells in terms of improved myocardial perfusion,
eduction in infarct size, and subsequent improved recovery
f LV function as compared with controls (inactive serum)
t mid-term and long-term follow-up. “These 3 studies
ere good examples of how imaging can be used to track
ew therapies,” said Dr. Villanueva.
uestion and Answer
r. Thomas: It’s an interesting concept to study those
false-positive” patients. We feel like we’ve done a bad thing
f we send a patient to the cath lab and it’s negative. We say
t’s a false-positive test, but the data suggest it may really
ean something in terms of prognosis.
r. Villanueva: Exactly. sr. Harrington: I don’t think there is anything wrong with
ending them to the cath lab when there is a level of
ncertainty. In fact, that’s a reasonable recommendation to
end people for angiography.
r. Thomas: Also, if it’s a real hard read on the ischemia
here, it probably means you need to look carefully for
hat’s causing that ischemia even if it isn’t epicardial
oronary disease.
r. Harrington: And the other information you get in the
ath lab, Jim, as you know, is a measure of end-diastolic
ressure. We can do a right-heart cath. We can provide
dditional diagnostic information that may be helpful in
hat particular group of patients.
r. Villanueva: The study really highlights how perfusion
maging gives you different information than catheteriza-
ion. It weighs in on the strength of physiologic imaging
nd functional imaging for assessing patients above and
eyond just anatomic imaging.
r. Tuzcu: Liza, if we have to go back to our offices and tell
olleagues 2 or 3 things that probably will change practice,
ven to a small degree, do you think that PET is one of
hem? Or will it be more utilization of CT in the emergency
oom?
r. Villanueva: I think the jury is still out on a lot these
maging studies because the numbers have been small and
e don’t have long-term follow-up on some these trials.
here is strong promise and confirmation that some sort of
iability assessment will help to risk stratify patients who
ould benefit from revascularization. We are starting to sort
hrough all of the data with CT and it does have very strong
egative predictive value, because it’s such a sensitive test,
ut it still suffers from positive predictive value issues.
r. Thomas: I was glad to see those data from Matt Budoff
ecause I think there has been a lot of long-term data on
alcification because the technology goes back 10 years.
ow, for the first time, we are seeing some long-term data
n prognosis from CTA. The jury is out in terms of exactly
ow we integrate this into our practice, especially consid-
ring radiation risks and things like that. But it’s data like
r. Budoff’s that will define the utility of CTA.
r. DeMaria: If you ask me for my take-home message on
maging, it’s just what Liza said: we didn’t get a take-home
essage. We got small studies that were nondefinitive and
e still don’t understand the role of all these studies. Even
he PARR-2 trial—35% of the people recommended to
ave revascularization never received it. So, there is not a lot
’m going to do differently tomorrow based on what was
resented here.
r. Conti: Just one quick comment. We have laid aside
oronary angiography and ventriculography and never really
ooked at it as carefully as we like. In these days when every
of these patients has had coronary angiography and
entriculography, every 1 of them has proximal stenoses and
ood distal vessels, otherwise we wouldn’t be bothering
ooking for viability. We need to look at myocardial perfu-
ion at the microvascular level. We need to look at collat-
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e’re pretty sloppy in the cath lab in terms of angiography.
think we need to take a step back and look harder at that.
r. Tuzcu: You really hit something very dear to my heart.
ou are absolutely right. We probably use only 10% of the
nformation we get from a good left-heart catheterization. I
ill add to that some hemodynamic data that we can gather
ith careful assessment. If you look at those ventriculogra-
hies and coronary angiographies outside the coronary
rteries, you will find a lot of things.
r. Starling: And there will be hopefully a large body of
nformation that comes from the STICH (Surgical Treat-
ents for Ischemic Heart Failure) trial that won’t random-
ze patients based on viability studies, but it will be collected
n a very prospective manner. So, a lot more yet to learn in
hat area.
ediatric Cardiology and
dult Congenital Heart Disease
n the basis of abstract submissions by topic, a total of 191
bstracts relating to pediatric cardiology and adult congen-
tal heart disease were submitted to the ACC.07 Scientific
ession Program Committee. Of these submissions, 76
ere selected for presentation. Dr. Rhodes summarized key
essions and noted at the beginning, “Pediatric cardiology is
ort of a different world than everyone else on this panel
ives in. We don’t have as many resources to develop
egistries and do clinical trials and we don’t have the patient
olumes to answer things as accurately as other specialties.”
hat being said, he added, pediatric cardiology is growing
uickly—even if patient volume is not—because the sur-
ival of patients is improving, “so much so that the adult
ongenital population is growing tremendously. Everyone in
his audience needs to start thinking about learning a little
bout congenital heart disease,” said Dr. Rhodes.
The first paper he discussed evaluated a prenatal cardiac
ntervention presented by Doff B. McElhinney, MD, of
hildren’s Hospital, Boston (86). Hypoplastic left heart
yndrome frequently is diagnosed prenatally and, during a
-year period, 80 fetuses have undergone a prenatal cardiac
ntervention via percutaneous entry through the chest wall
f the mother, through the uterus, and through the free wall
f the left ventricle. Once the needle is in position, a
uidewire is placed followed by “a coronary balloon, believe
t or not,” to open the aortic valve and improve flow to the
eft ventricle. Of the percutaneous in utero cardiac interven-
ions, 63 (79%) were successful. All fetuses regained normal
eart rate and ventricular function after 1 to 32 min.
The hypothesis was that fetal aortic valvuloplasty may
revent progression of AS to hypoplastic left heart syn-
rome. In reviewing fetal echocardiograms before interven-
ion and then 2 years later, endocardial fibroelastosis and the
mall, thickened chamber showed significant improvement.
This technology is going to continue to develop, mainly in
arge medical centers,” said Dr. Rhodes, “We don’t knowxactly which direction it’s going to go, but it has a lot of
pplication.”
Peak oxygen consumption, VE/VCO2 slope, and param-
ters of heart rate response were recently identified as strong
redictors of mortality in adult congenital heart disease
ACHD) patients. Diller et al. (87) compared the prognos-
ic power of exercise parameters in a large population of
atients with ACHD. Ventilatory efficiency and heart rate
eserve were the strongest exercise predictors of survival in
dults with noncyanotic ACHD and, in combination,
rovided an invaluable clinical tool for risk stratification.
According to a population-based study, a large percent-
ge of children and adults with congenital heart disease are
ost to follow-up (88). The study population consisted of
ndividuals born in 1983 and alive at age 22 who were
iagnosed with congenital heart disease by a cardiologist in
uebec, Canada, before 6 years of age (n  563). Patients
ere typically without cardiology follow-up through child-
ood and adolescence; so much so that only 39% were still
eeing a cardiologist as young adults (Fig. 18). Even among
atients with lesions that generally warrant lifelong follow-
p, a substantial proportion of patients were no longer being
een within the pediatric age range.
Historically, young children have constituted the age
roup with the greatest mortality from congenital heart
isease. Again, investigators at McGill University in Mon-
real, Quebec, conducted a population-based study to assess
ge-specific mortality trends during an 18-year period (89).
hildhood mortality has decreased dramatically during this
ime and, as Dr. Rhodes explained, “What’s interesting
bout this is it’s in the most complex cardiac conditions
here mortality is falling.” As the authors noted, there are
mportant consequences to the fact that congenital heart
isease deaths have shifted away from the young and
owards the adult, with increasing absolute numbers and
ortality rates (Fig. 19). They noted, “The health care
ommunity must prepare to meet this new reality.”
Figure 18 Proportion of Children and Young Adults With CHD
Receiving Outpatient Care Declines With Age
CHD  congenital heart disease.
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ACC 2007 Annual Session Highlights August 21, 2007:C2–31Coarctation of the aorta leads to impaired endothelial
unction that persists many years after successful surgical
epair. Brilli et al. (90) examined the effect of ramipril on
ndothelial function and inflammation in young normoten-
ive subjects with successfully repaired coarctation of the
orta. Twenty patients received ramipril 5 mg/day or no
reatment for 4 weeks in a randomized crossover prospective
rial with a 4-week washout period between interventions.
ndothelium-dependent dilation was significantly im-
roved after ramipril treatment but not after no treatment.
aximum hyperemic flow also was increased only with
amipril therapy. Serum interleukin-6 was decreased after
amipril treatment but remained unchanged in controls.
ccording to Dr. Rhodes, endothelial dysfunction and
ncreased inflammatory markers may both be very valuable
o follow in these patients over time.
hallenges of Contraception
ne ACC.07 symposium focused on Family Planning for
dult Congenital Heart Disease Patients. This can be a
hallenge given that women with congenital heart disease
re often told they are at too high a risk for pregnancy, but
lso too high a risk for many of the available contraceptives,
ncluding those that are estrogen-based. There are several
ptions (91). Progestin-only birth control methods are
ssociated with little or no increased risk of cerebrovascular
ccident or AMI; there is a small, nonsignificant increase in
he odds ratio for venous thromboembolism; and the evi-
ence is encouraging regarding safe use in women with
ypertension, although more studies are needed. Effective-
ess of a progestin-only pill is the same as the combined
Figure 19 Changing Age Distribution of Death in CHD From
1988 to 2005 From a Population-Based Study
CHD  congenital heart disease.strogen/progestin pill (92% for both), but oral progestin- inly contraception is highly time sensitive, requiring daily
se and use at about the same time every day. Also, a
rogestin-only pill may affect international normalized ra-
io, especially when initiating therapy.
Longer-lasting options are available. IMPLANON is a
mall, thin, implantable hormonal contraceptive that is
ffective for up to 3 years. Also, progestin-only injectables
re available: Depo-Provera, which is administered by a
ealth care professional, and Depo-SubQ Provera, which
an be self-administered monthly. Although fraught with
ontroversy for many years, an intrauterine device has a low
ncidence of pelvic inflammatory disease and contraceptive
fficacy equivalent to that of combined oral contraceptives.
t has been approved for women at risk of endocarditis.
Progesterone-only methods and intrauterine devices could
e even more effective in preventing unwanted pregnancy in
ongenital heart patients,” said Dr. Rhodes, adding that
revention of teenage pregnancy is “also very critical” and
equires a sexual history and a frank discussion to try to
revent pregnancy in teenage girls with congenital heart
isease.
Finally, as interventional cardiologists consider the po-
ential of a bioabsorbable stent, new bioabsorbable closure
echnology is being evaluated for advanced septal repair of
CHD. Said Dr. Rhodes, “This is going to have a lot of
pplications for patients with congenital heart disease.”
uestion and Answer
r. Thomas: Let’s see you do one of those percutaneous
etal interventions live at i2 next year, Bill.
r. Knopf: We may be doing one of those live next year.
r. Thomas: You have got to come to Chicago, folks.
r. Tuzcu: Thank you, John; a wonderful overview and very
xciting. We are delighted to have Pediatric Cardiology and
ediatric Cardiac Surgery in our program, and Bill will
ttest to that. We are moving forward to form more bridges
ith pediatric cardiology interventions, which really form
he basis of many of our structural heart disease interven-
ions. I very much welcome your contribution to that.
pecial Topics
t ACC.07, 239 abstracts were submitted in the Special
opics category, 92 of which were accepted for presenta-
ion. Dr. Foody was given the opportunity to present
ighlights from these papers. Overall, she said, the scientific
essions “speak to the diversity, the innovation of the
ardiovascular community.” Giving what she said is the
30,000-foot view,” it’s clear that among the ACC.07/i2
ummit sessions “tremendous technological advances” were
ighlighted; yet she harkened back to a quote from Marc A.
feffer, MD, PhD, FACC, who at the Opening Session
elivered the year’s Simon Dack Lecture, “Seeking Balance:
esearch and Education.” Said Dr. Pfeffer: “Trials in
solation are a hollow victory.”
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aking significant strides,” said Dr. Foody, although there
s still some distance to go given that a review of 439
ndications of quality of care found that patients receive only
5% of recommended care and all demographic groups are
t risk of poor quality of care. “But we have the ACC’s effort
o develop a comprehensive national cardiovascular registry,
he ACTION Registry, to address this,” she added.
Among the exciting issues from ACC.07, she said, were
he CRUSADE Initiative data. “We’ve seen dramatic in-
reases over the last several years with respect to overall
dherence trends in cardiovascular care,” she said (Fig. 20),
nd the data are echoed in multiple registries with respect to
are. “However, as much as this care is significantly im-
roved, significant gaps remain and hopefully lessons
earned here from Special Topics will help develop inter-
entions that continue to advance the application of
vidence-based care to our patients,” she said.
Also from the opening ceremony, she quoted Steven E.
issen, MD, MACC, from his presidential address: “His-
ory will judge us not by our scientific progress, but by how
e treat the weakest and most vulnerable among us.” Many
f the Special Topics, she said, focused on identifying these
ulnerable populations and then providing therapies and
nterventions to improve their outcome.
“It is certainly apropos that we sit here in New Orleans,”
aid Dr. Foody. “We’ve all been struck by the effect of
Hurricane] Katrina,” which she said amplified deficiencies,
ulnerabilities, and disparities in heath care. “We have a
remendous opportunity and Special Topics has really led
he way in research looking at innovations and improving
are for those patients who are most vulnerable.”
r. Tuzcu: Thank you, JoAnne. Dr. Conti, Dr. DeMaria,
hank you very much for being with us; you have been very,
ery helpful. To the topic coordinators, we thank you; as the
o-chairs, we deeply appreciate your input.
And we conclude the 56th Scientific Session of the
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Available at:
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